Report according to § 42b (2) German Drug Law

Protocol-No.:	**BO20906 (BETH)**
Study Title:	A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab
Date of Report:	Final Clinical Study Report 1061423 (December 2014) Primary Clinical Study Report 1056851 (April 2014)
Study Sponsor(s)	F. Hoffmann-La Roche Ltd, Switzerland (Sponsor in Europe)
Study Date:	**Final Clinical Study Report 1061423 (December 2014):** First Patient Entered: 01 May, 2008 Last Patient Entered: 10 December, 2010 LPLV: 17 April 2014 Database lock: 10 July, 2014 This CSR covers the period from 30 June, 2013 (cut-off for the primary analysis) until LPLV on 17 April 2014. **Primary Clinical Study Report 1056851 (April 2014):** First Patient Entered: 01 May, 2008 Last Patient Entered: 10 December, 2010 Clinical Cut-off: 30 June, 2013
Trial Phase:	III
Indication:	breast cancer
Name of Finished Product:	Avastin® Herceptin® Taxotere®
Name of Active Substance:	Bevacizumab Trastuzumab Docetaxel

Number of Patients: Planned: 3500
Randomised: 3509

Chemotherapy + Herceptin: N = 1757

(Group 1A: TCH→H; N = 1617)

(Group 2A: TH→FEC→H; N = 140)

Chemotherapy + Herceptin + Bevacizumab: N = 1752

(Group 1B: TCHB→HB; N = 1614)

(Group 2B: THB→FEC→HB; N = 138)

Disposition of Patients (ITT Population):



Source: ec11_i001, ex15a_i001, dm11spdisp_i001
Bv = bevacizumab, Chemo = chemotherapy; H = Herceptin (trastuzumab).

[b] 1 patient randomized to receive Chemo+H received Chemo+H+Bv.
[c] 11 patients randomized to receive Chemo+H+Bv received Chemo+H.

Study Interruptions/ Premature end:

Study was prematurely ended:

The BO20906 (BETH) study did not meet its primary endpoint of demonstrating a benefit from the addition of bevacizumab to THC (docetaxel, carboplatin, trastuzumab). All patients have been off treatment since December 2011 or before. There were no efficacy benefits accrued to patients with use of bevacizumab and there were no new safety concerns found when examining the study data. For these reasons Roche has decided to close the study early effective immediately.

Synopsis of final report 1061423 (December 2014)

Study BO20906

Data cut-off:	LPLV: 17 April 2014
Period covered by this report:	30 June 2013 (cut-off for the primary analysis) to LPLV on 17 April 2014.

SYNOPSIS OF RESEARCH REPORT 1061423 (PROTOCOL BO20906)

COMPANY: NAME OF FINISHED PRODUCT: NAME OF ACTIVE SUBSTANCE(S):	

TITLE OF THE STUDY / REPORT No. / DATE OF REPORT	**Final Clinical Study Report** - BO20906 - A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab. Report No. 1061423. December, 2014.
INVESTIGATORS / CENTERS AND COUNTRIES	Western Europe: Austria, Belgium, Germany, France, Greece, Ireland, Italy, Portugal, Spain, Sweden, United Kingdom Eastern Europe: Bosnia-Hercegovina, Bulgaria, Croatia, Estonia, Hungary, Latvia, Poland, Romania, Russia, Serbia, Slovenia North America: Canada, United States Central and South America: Argentine, Brazil, Mexico, Peru Asia and Pacific: Australia, China, Korea, Philippines, Thailand, Taiwan Other: Egypt, Israel, South Africa
PUBLICATION (REFERENCE)	None
PERIOD OF TRIAL	First Patient Entered: 01 May, 2008 Last Patient Entered: 10 December, 2010 LPLV: 17 April 2014 Database lock: 10 July, 2014 This CSR covers the period from 30 June, 2013 (cut-off for the primary analysis) until LPLV on 17 April 2014.
CLINICAL PHASE	III
OBJECTIVES	Primary objective: To determine whether the addition of bevacizumab to the two designated regimens of chemotherapy + trastuzumab (TCHB→HB; THB→FEC→HB) improves invasive disease-free survival relative to the two designated regimens of chemotherapy + trastuzumab (TCH→H; TH→FEC→H).
STUDY DESIGN	International, multi-center, open-label, randomized, Phase III trial
NUMBER OF SUBJECTS	Planned: 3500 patients overall. Enrolled: 3509 patients overall. Chemotherapy + Herceptin: N = 1757 (Group 1A: TCH→H; N = 1617) (Group 2A: TH→FEC→H; N = 140)

	Chemotherapy + Herceptin + Bevacizumab: N = 1752 (Group 1B: TCHB→HB; N = 1614) (Group 2B: THB→FEC→HB; N = 138)
DIAGNOSIS AND MAIN CRITERIA FOR INCLUSION	Pre- and postmenopausal female patients with HER2-positive, node-positive or high risk node-negative invasive adenocarcinoma of the breast. Age ≥18 years old Unilateral invasive primary pT1–T3 breast carcinoma, node positive or high-risk node negative (at least one of the following: >2cm; ER and PgR negative; grade 2 or 3; age <35 years) Centrally tested HER2-positive disease (FISH+ or IHC3+) Undergone total mastectomy or breast-conserving surgery completed 4–12 weeks before randomization LVEF ≥55% ECOG PS 0/1
TRIAL DRUG / STROKE (BATCH) No.	Bevacizumab: Batch Numbers. See Primary CSR (Roche Report No. 1056851).
DOSE / ROUTE / REGIMEN / DURATION	15 mg/kg IV every 3 weeks (q3w) for 1 year.
REFERENCE DRUG / STROKE (BATCH) No.	Trastuzumab; Docetaxel: Carboplatin: 5-FU; Epirubicin; Cyclophosphamide
DOSE / ROUTE / REGIMEN / DURATION	Trastuzumab: Group 1A and 1B - 1st dose 8 mg/kg IV, subsequent doses 6 mg/kg IV / q3w x 1 year; Group 2A and 2B - 1st dose 8 mg/kg IV, doses 2 and 3 - 6 mg/kg IV; dose 4 - 8 mg/kg IV, subsequent doses 6 mg/kg IV / q3w x 1 year. Docetaxel; Group 1A and 1B - 75 mg/m^2 IV / q3w x 6 cycles; Group 2A and 2B - 100 mg/m^2 IV / q3w x 6 cycles. Carboplatin: Group 1A, 1B, 2A, 2B: AUC = 6 mg/mL/min IV / q3w x 6 cycles. 5-FU: 600 mg/m^2 IV; Epirubicin: 90 mg/m^2 IV; Cyclophosphamide: 600 mg/m^2 IV / q3w x 3 cycles.
CRITERIA FOR EVALUATION	
EFFICACY:	Primary parameter: Invasive Disease Free Survival (IDFS). Secondary parameters: IDFS within the chemotherapy cohorts, disease-free survival (DFS), overall survival (OS), recurrence-free interval (RFI), distant recurrence-free interval (DRFI). Biomarkers
SAFETY:	Adverse events (cardiac and non-cardiac toxicity), laboratory tests, vital signs, ECOG PS.
STATISTICAL METHODS	The statistical methods used for the analysis of the primary and secondary efficacy endpoints are shown in the Primary CSR (Roche Report No. 1056851).

METHODOLOGY

Patients in study BO20906 were enrolled in one of two chemotherapy groups. One group received 6 cycles of docetaxel/carboplatin plus trastuzumab with or without bevacizumab (TCH→H or TCHB→HB); the other group received 3 cycles of docetaxel plus trastuzumab given with or without bevacizumab followed by 3 cycles of FEC (TH→FEC→H or THB→FEC→HB). With both regimens, patients continued trastuzumab with or without

bevacizumab following chemotherapy to complete 1 year of targeted therapy. Following completion of chemotherapy, patients received adjuvant radiotherapy and endocrine therapy as clinically indicated.

Adverse events were reported in two safety cohorts:

- Cohort1 (standard reporting): Until 18 months post randomization - first 300 patients enrolled in each group - all grades of AEs reported.
- Cohort 2 (limited reporting): Until 18 months post randomization - patients enrolled after the first 300 patients in each group - ≥ Grade 2 AESIs; Grade 1 and 2 AEs requiring change in treatment; all grade 3 & 4 AEs.
- Both cohorts: After 18 months and for the remainder of the follow-up - ongoing and newly occurring treatment related Grade 3 & 4 AEs, ≥ Grade 2 AESIs regardless of causality and SAEs considered to be related to study treatment/procedures.

Results of the efficacy (primary and secondary endpoints) and safety data up to the clinical cut-off date of 30 June, 2013 were reported in the Primary CSR (Roche Report No. 1056851) dated April 2014.

Study BO20906 did not meet its protocol specified primary endpoint of Invasive Disease-Free Survival (IDFS). Bevacizumab when combined with chemotherapy plus trastuzumab and continued for a treatment duration of one year did not prolong IDFS compared to chemotherapy plus trastuzumab in the adjuvant treatment of HER2-positive node positive or high risk node-negative breast cancer.

This final CSR has been prepared in an abbreviated format as it primarily reports the safety data collected between the clinical cut off for the primary analysis (30 June, 2013) and LPLV (17 April, 2014). During this period, patients were in post-study treatment follow-up and were not receiving study treatment (i.e., bevacizumab, trastuzumab or chemotherapy).

Since special attention was focused on the cardiac safety of the combination treatments used in this trial, the data presented in this report covers the entire duration of the trial (01 May, 2008 to 17 April, 2014).

This report does not include any efficacy data in addition to that reported in the Primary CSR (Roche Report No. 1056851).

SAFETY RESULTS

The safety data reported during the period from June 30, 2013 to 17 April, 2014 resulted in the following:

- The overall incidence of AEs in both treatment arms was low during the period covered by this report.
- The proportion of patients with at least one AE (all grades) was similar in the two treatment arms (Chemo+H, 1.1%; Chemo+H+Bv, 1.3%).
- The proportion of patients with a SAE was similar in the two treatment arms (Chemo+H, 0.1%; Chemo+H+Bv, 0.2%).
- The proportion of patients with Grade $\geq$ 3 AEs was the same in the two treatment arms (Chemo+H arm, 0.3%; Chemo+H+Bv arm, 0.3%).
- Grade 5 AEs were not reported in either treatment arm.
- AESIs were reported at a similar frequency in both treatment arms.

Overview of Safety (Safety Population)

Adverse Event	Chemo+H (N=1750) n	(%)	Chemo+H+Bv (N=1722) n	(%)
General Adverse Events #:				
Pts w. AE	20	(1.1%)	23	(1.3%)
Pts w. Serious AE	1	(0.1%)	3	(0.2%)
Pts w. Grade 3/4/5 AE	5	(0.3%)	6	(0.3%)
Pts w. Grade 5 AE (Outcome Death)	0	(0.0%)	0	(0.0%)
Pts who Disc. Bev Treatment due to AE ##	0	(0.0%)	0	(0.0%)
Pts who Disc. Trial Treatment due to AE ##	0	(0.0%)	0	(0.0%)
All Deaths	14	(0.8%)	14	(0.8%)
Deaths not due to Recurrence	4	(0.2%)	3	(0.2%)
AE of Special Interest for Bevacizumab ###:				
Pts w. AE of Special Interest	20	(1.1%)	16	(0.9%)
Pts w. AE of Special Interest Grade 3/4/5	5	(0.3%)	5	(0.3%)
Pts w. Serious AE of Special Interest	1	(0.1%)	2	(0.1%)
Pts w. Bleeding	0	(0.0%)	0	(0.0%)
Pts w. Congestive Heart Failure	3	(0.2%)	4	(0.2%)
Pts w. Abscesses and Fistulae	0	(0.0%)	0	(0.0%)
Pts w. Gastrointestinal Perforations	0	(0.0%)	0	(0.0%)
Pts w. Hypertension	13	(0.7%)	7	(0.4%)
Pts w. Proteinuria	0	(0.0%)	0	(0.0%)
Pts w. PRES	0	(0.0%)	0	(0.0%)
Pts w. Arterial Thromboembolic Events	4	(0.2%)	5	(0.3%)
Pts w. Venous Thromboembolic Events	0	(0.0%)	0	(0.0%)
Pts w. Wound Healing Complication	0	(0.0%)	0	(0.0%)

#,### Includes AEs that started after the last clinical cut-off for the primary analysis, 30th June 2013
Note that there were no patients on study treatment during the period covered by this table. Hence, no patients could be withdrawn from bevacizumab or trial treatment

Program : $PROD/cdp10044/i20906b/saefu_11.sas
Output : $PROD/cdp10044/i20906b/reports/saefu_11_S001.lst
06AUG2014 12:14

In this study where special attention was focused on the cardiac safety of the treatment combinations administered, the overall frequency of cardiovascular events from the start of treatment was higher in the Chemo+H+Bv arm (51% patients) than in the Chemo+H arm (26% patients). This was mainly driven by an increased incidence in hypertension (43% vs. 15%). The rate per 100 patient years for hypertension events was higher in the Chemo+H+Bv arm (20.0) than in the Chemo+H arm (4.8), and to a lesser extent for left ventricular dysfunction events (3.4 in the Chemo+H+Bv arm vs. 2.5 in the Chemo+H arm).

Declines in LVEF of ≥ 10% and to below 55% and LVEF decreases of more than 5% to less than the lower limit of normal were more apparent in the Chemo+H+Bv arm (13.3% patients and 23.0% patients, respectively), than in the Chemo+H arm (10.3% patients and 18.3% patients, respectively).

CONCLUSIONS

Overall, no new or unexpected safety signals were observed when compared with those reported during the treatment phase of the study. The cardiac safety profile was consistent with that observed in prior studies with bevacizumab.

The overall safety profile was consistent with other studies in which patients with breast cancer had received bevacizumab therapy.

Synopsis of primary report 1056851 (April 2014)

Study BO20906

Data cut-off: 30 June 2013 (primary analysis)

SYNOPSIS OF RESEARCH REPORT 1056851 (PROTOCOL BO20906)

COMPANY: NAME OF FINISHED PRODUCT: NAME OF ACTIVE SUBSTANCE(S):	

TITLE OF THE STUDY / REPORT No. / DATE OF REPORT	**Primary Clinical Study Report** - BO20906 - A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab. Report No. 1056851. April 2014
INVESTIGATORS / CENTERS AND COUNTRIES	Western Europe: Austria, Belgium, Germany, France, Greece, Ireland, Italy, Portugal, Spain, Sweden, United Kingdom Eastern Europe: Bosnia-Hercegovina, Bulgaria, Croatia, Estonia, Hungary, Latvia, Poland, Romania, Russia, Serbia, Slovenia North America: Canada, United States Central and South America: Argentine, Brazil, Mexico, Peru Asia and Pacific: Australia, China, Korea, Philippines, Thailand, Taiwan Other: Egypt, Israel, South Africa
PUBLICATION (REFERENCE)	None
PERIOD OF TRIAL	First Patient Entered: 01 May, 2008 Last Patient Entered: 10 December, 2010 Clinical Cut-off: 30 June, 2013
CLINICAL PHASE	III
OBJECTIVES	Primary objective: To determine whether the addition of bevacizumab to the two designated regimens of chemotherapy + trastuzumab (TCHB→HB; THB→FEC→HB) improves invasive disease-free survival relative to the two designated regimens of chemotherapy + trastuzumab (TCH→H; TH→FEC→H).
STUDY DESIGN	International, multi-center, open-label, randomized, Phase III trial
NUMBER OF SUBJECTS	Planned: 3500 patients overall. Enrolled: 3509 patients overall. Chemotherapy + Herceptin: N = 1757 (Group 1A: TCH→H; N = 1617) (Group 2A: TH→FEC→H; N = 140) Chemotherapy + Herceptin + Bevacizumab: N = 1752 (Group 1B: TCHB→HB; N = 1614) (Group 2B: THB→FEC→HB; N = 138)

DIAGNOSIS AND MAIN CRITERIA FOR INCLUSION	Pre- and postmenopausal female patients with HER2-positive, node-positive or high risk node-negative invasive adenocarcinoma of the breast. Age ≥18 years old Unilateral invasive primary pT1–T3 breast carcinoma, node positive or high-risk node negative (at least one of the following: >2cm; ER and PgR negative; grade 2 or 3; age <35 years) Centrally tested HER2-positive disease (FISH+ or IHC3+) Undergone total mastectomy or breast-conserving surgery completed 4–12 weeks before randomization LVEF ≥55% ECOG PS 0/1
TRIAL DRUG / STROKE (BATCH) No.	Bevacizumab: Batch Numbers. See Clinical Study Report text
DOSE / ROUTE / REGIMEN / DURATION	15 mg/kg IV every 3 weeks (q3w) for 1 year.
REFERENCE DRUG / STROKE (BATCH) No.	Trastuzumab; Docetaxel: Carboplatin: 5-FU; Epirubicin; Cyclophosphamide
DOSE / ROUTE / REGIMEN / DURATION	Trastuzumab: Group 1A and 1B - 1st dose 8 mg/kg IV, subsequent doses 6 mg/kg IV / q3w x 1 year; Group 2A and 2B - 1st dose 8 mg/kg IV, doses 2 and 3 - 6 mg/kg IV; dose 4 - 8 mg/kg IV, subsequent doses 6 mg/kg IV / q3w x 1 year. Docetaxel; Group 1A and 1B - 75 mg/m^2 IV / q3w x 6 cycles; Group 2A and 2B - 100 mg/m^2 IV / q3w x 6 cycles. Carboplatin: Group 1A, 1B, 2A, 2B: AUC = 6 mg/mL/min IV / q3w x 6 cycles. 5-FU: 600 mg/m^2 IV; Epirubicin: 90 mg/m^2 IV; Cyclophosphamide: 600 mg/m^2 IV / q3w x 3 cycles.
CRITERIA FOR EVALUATION	
EFFICACY:	Primary parameter: Invasive Disease Free Survival (IDFS): Time from randomization to local recurrence or second primary cancer (other than squamous or basal cell carcinoma of the skin, carcinoma in situ of the cervix, colon carcinoma in situ, or lobular carcinoma in situ of the breast), or death from any cause prior to recurrence or second primary cancer. Secondary parameters: IDFS within the chemotherapy cohorts, disease-free survival (DFS), overall survival (OS), recurrence-free interval (RFI), distant recurrence-free interval (DRFI). Biomarkers
SAFETY:	Adverse events (cardiac and non-cardiac toxicity), laboratory tests, vital signs, ECOG PS.
STATISTICAL METHODS	The Kaplan-Meier product limit method was used to estimate the IDFS. The log-rank test at the 5% alpha level, stratified for background chemotherapy regimen, nodal status (N0 versus N1−3 versus N4+), and hormonal receptor status (estrogen and/or progesterone receptor positive versus negative), was used to perform all comparisons between treatment arms with respect to IDFS. Confidence intervals of the median IDFS was calculated using the Brookmeyer and Crowley method.

METHODOLOGY

Patients in study BO20906 were enrolled in one of two chemotherapy groups. One group received 6 cycles of docetaxel/carboplatin plus trastuzumab with or without bevacizumab (TCH→H or TCHB→HB); the other group received 3 cycles of docetaxel plus trastuzumab given with or without bevacizumab followed by 3 cycles of FEC (TH→FEC→H or THB→FEC→HB). With both regimens, patients continued trastuzumab with or without bevacizumab following chemotherapy to complete 1 year of targeted therapy. Following completion of chemotherapy, patients received adjuvant radiotherapy and endocrine therapy as clinically indicated.

Adverse events were reported in two safety cohorts:

- Cohort1 (standard reporting): Until 18 months post randomization - first 300 patients enrolled in each group - all grades of AEs reported.
- Cohort 2 (limited reporting): Until 18 months post randomization - patients enrolled after the first 300 patients in each group - ≥ Grade 2 AESI; Grade 1 and 2 AEs requiring change in treatment; all grade 3 & 4 AEs.
- Both cohorts: After 18 months and for the remainder of the follow-up - ongoing and newly occurring treatment related Grade 3 & 4 AEs, ≥ Grade 2 AESI regardless of causality.

Results of the primary and secondary efficacy data reported in this CSR are presented in an abbreviated form as data will not be used to support an efficacy claim. Safety data from this study are reported in full in this CSR.

EFFICACY RESULTS

Study BO20906 did not meet its protocol specified primary endpoint of Invasive Disease-Free Survival (IDFS). Bevacizumab when combined with chemotherapy plus trastuzumab and continued for a treatment duration of one year in combination with trastuzumab did not prolong IDFS in the adjuvant treatment of HER2-positive node positive or high risk node-negative breast cancer.

The hazard ratio for IDFS was 0.99 (95% CI [0.79; 1.25]). The stratified log-rank test p-value was 0.9610. The Kaplan–Meier estimated median duration of IDFS was not reached in either treatment arm.

In the unstratified analysis, the hazard ratio for IDFS was 1.02 (95% CI [0.81; 1.28]); log-rank test p-value was 0.8796.

In the analysis in which patients with a second primary malignancy were excluded (U.S. analysis), the hazard ratio for IDFS was 1.06 (95% CI [0.83; 1.35]). The stratified log-rank test p-value was 0.6428. The Kaplan–Meier estimated median duration of IDFS was not reached in either treatment arm.

Treatment with Chemo+H+Bv compared with Chemo+H did not prolong the secondary efficacy parameters of disease-free survival, overall survival (interim analysis), recurrence-free interval or distant recurrence-free interval.

Summary of Key Primary and Secondary Efficacy Results by Trial Treatment (ITT)

	Chemo+H (N=1757)		Chemo+H+Bv (N=1752)
Primary Efficacy parameter			
Invasive Disease-Free Survival (IDFS)			
Patients with event	145 (8.3 %)		147 (8.4 %)
Patients without events**	1612 (91.7 %)		1605 (91.6 %)
Time to event (months)			
Median###	.		.
p-Value (Log-Rank Test, Stratified $)		0.9610	
Hazard Ratio (Stratified $)		0.99	
95% CI		[0.79;1.25]	

Summary of Key Primary and Secondary Efficacy Results by Trial Treatment (ITT) (Cont)

	Chemo+H (N=1757)		Chemo+H+Bv (N=1752)
IDFS, Excl. Sec. Prim. Non-BIC			
Patients with event	126 (7.2 %)		136 (7.8 %)
Patients without events**	1631 (92.8 %)		1616 (92.2 %)
Time to event (months)			
Median###	.		.
p-Value (Log-Rank Test, Stratified $)		0.6428	
Hazard Ratio (Stratified $)		1.06	
95% CI		[0.83;1.35]	
Secondary Efficacy parameters			
Disease-Free Survival			
Patients with event	145 (8.3 %)		151 (8.6 %)
Patients without events**	1612 (91.7 %)		1601 (91.4 %)
Time to event (months)			
Median###	.		.
p-Value (Log-Rank Test, Stratified $)		0.8402	
Hazard Ratio (Stratified $)		1.02	
95% CI		[0.81;1.29]	
Overall Survival			
Patients with event	62 (3.5 %)		54 (3.1 %)
Patients without events**	1695 (96.5 %)		1698 (96.9 %)
Time to event (months)			
Median###	.		.
p-Value (Log-Rank Test, Stratified $)		0.5147	
Hazard Ratio (Stratified $)		0.89	
95% CI		[0.61;1.28]	
Recurrence-Free Interval			
Patients with event	111 (6.3 %)		125 (7.1 %)
Patients without events**	1646 (93.7 %)		1627 (92.9 %)
Time to event (months)			
Median###	.		.
p-Value (Log-Rank Test, Stratified $)		0.4331	
Hazard Ratio (Stratified $)		1.11	
95% CI		[0.86;1.43]	
Distant Recurrence-Free Interval			
Patients with event	94 (5.4 %)		103 (5.9 %)
Patients without events**	1663 (94.6 %)		1649 (94.1 %)
Time to event (months)			
Median###	.		.
p-Value (Log-Rank Test, Stratified $)		0.5829	
Hazard Ratio (Stratified $)		1.08	
95% CI		[0.82;1.43]	

Time to CSIDFS [months] (TTMIDFS) - Censoring: Invasive Disease Free Survival (CSIDFS)
Time to CSIDFSM [months] (TTMIDFSM) - Censoring: IDFS, Excl. Sec. Prim. Non-BIC (CSIDFSM)
Time to CSDFS [months] (TTMDFS) - Censoring: Disease Free Survival (CSDFS)
Time to Death [months] (TTMDIED) - Censoring: Overall survival (CSDIED)
Time to RFI [months] (TTMRFI) - Censoring: Recurrence Free Interval (CSRFI)
Time to CSDRFI [months] (TTMDRFI) - Censoring: Distant Recurrence Free Survival (CSDRFI)
** censored
Kaplan-Meier estimates

SAFETY RESULTS

Cohort 1

The safety data reported during the period from randomization to 18 months for Cohort 1 patients resulted in the following:

- The proportion of patients with at least one AE (all grades) was similar in the two treatment arms (Chemo+H, 97.9%; Chemo+H+Bv, 97.6%).
- The proportion of patients with a SAE was higher in the Chemo+H+Bv arm (34.3%) than in the Chemo+H arm (22.1%).
- The proportion of patients with Grade ≥ 3 AEs was higher in the Chemo+H+Bv arm (72.7%) than in the Chemo+H arm (63.3%).
- Grade 5 AEs were reported with a low frequency in both treatment arms (Chemo+H, 0.7%; Chemo+H+Bv, 0.3%).
- More patients in the Chemo+H+Bv arm (19.2%) discontinued trial treatment due to an AE than in the Chemo+H arm (7.6%).
- Adverse events of special interest were reported more frequently in patients in the Chemo+H+Bv arm (83.9%) than in the Chemo+H arm (46.4%), as were Grade ≥ 3 AESIs (Chemo+H+Bv, 31.1%; Chemo+H 8.7%) and serious AESIs (Chemo+H+Bv, 5.9%; Chemo+H 2.1%). The increase in the overall incidence of AESIs in the Chemo+H+Bv arm compared with the Chemo+H arm was mainly due to a higher incidence of bleeding events (56.6% vs. 24.2%), hypertension (50.3% vs. 17.0%) and proteinuria (13.3% vs. 1.4%).

Overview of Safety: Cohort 1- Patients With all Adverse Events Reported With any Grade Until 18 Months After Randomization (SAP)

Adverse Event	Chemo+H (N=289) n (%)	Chemo+H+Bv (N=286) n (%)
General Adverse Events #:		
Pts w. AE	283 (97.9%)	279 (97.6%)
Pts w. Serious AE	64 (22.1%)	98 (34.3%)
Pts w. Grade 3/4/5 AE	183 (63.3%)	208 (72.7%)
Pts w. Grade 5 AE (Outcome Death)	2 (0.7%)	1 (0.3%)
Pts who Disc. Bev Treatment due to AE	1 (0.3%)	47 (16.4%)
Pts who Disc. Trial Treatment due to AE	22 (7.6%)	55 (19.2%)
All Deaths	5 (1.7%)	1 (0.3%)
Deaths not due to Recurrence	2 (0.7%)	1 (0.3%)
AE of Special Interest for Bevacizumab ##:		
Pts w. AE of Special Interest	134 (46.4%)	240 (83.9%)
Pts w. AE of Special Interest Grade 3/4/5	25 (8.7%)	89 (31.1%)
Pts w. Serious AE of Special Interest	6 (2.1%)	17 (5.9%)
Pts w. Bleeding	70 (24.2%)	162 (56.6%)
Pts w. Congestive Heart Failure	29 (10.0%)	40 (14.0%)
Pts w. Abscesses and Fistulae	0 (0.0%)	0 (0.0%)
Pts w. Gastrointestinal Perforations	1 (0.3%)	5 (1.7%)
Pts w. Hypertension	49 (17.0%)	144 (50.3%)
Pts w. Proteinuria	4 (1.4%)	38 (13.3%)
Pts w. PRES	0 (0.0%)	1 (0.3%)
Pts w. Arterial Thromboembolic Events	2 (0.7%)	6 (2.1%)
Pts w. Venous Thromboembolic Events	8 (2.8%)	12 (4.2%)
Pts w. Wound Healing Complication	6 (2.1%)	8 (2.8%)

#,## AE onset between time of very first drug intake and 18 months plus 28 days

Program : $PROD/cdp10044/bo20906/sae_11.sas
Output : $PROD/cdp10044/i20906a/reports/sae_11_S001_ALL.lst
06FEB2014 11:00 Page 1 of 1

Cohort 2

The safety data reported during the period from randomization to 18 months after randomization for Cohort 2 patients resulted in the following:

- The proportion of patients with at least one AE was higher in the Chemo+H+Bv, arm (90.7%) than in the Chemo+H arm (80.0%).

- The proportion of patients with a SAE was higher in the Chemo+H+Bv arm (33.0%) than in the Chemo+H arm (23.5%).
- The proportion of patients with Grade ≥ 3 AEs was higher in the Chemo+H+Bv arm (72.9%) than in the Chemo+H arm (61.5%).
- Grade 5 AEs were reported with a low incidence in both treatment arms (Chemo+H, 0.3%; Chemo+H+Bv, 0.6%).
- More patients in the Chemo+H+Bv arm (23.9%) discontinued trial treatment due to an AE than in the Chemo+H arm (5.7%).
- Adverse events of special interest were reported more frequently in patients in the Chemo+H+Bv arm (57.7%) than in the Chemo+H arm (20.7%), as were Grade ≥ 3 AESIs (Chemo+H+Bv, 25.2%; Chemo+H, 7.2%). The increase in the overall incidence of AESIs in the Chemo+H+Bv arm compared with the Chemo+H arm was mainly due to a higher incidence of hypertension (40.0% vs. 11.2%), bleeding events (11.8% vs. 2.0%), and proteinuria (6.7% vs. 0.6%).

Overview of Safety: Cohort 2 - Patients With AESIs Grade ≥ 2 and all AEs Grade ≥ 3 Until 18 Months After Randomization (SAP)

Adverse Event	Chemo+H (N=1461) n (%)	Chemo+H+Bv (N=1436) n (%)
General Adverse Events #:		
Pts w. AE	1169 (80.0%)	1302 (90.7%)
Pts w. Serious AE	344 (23.5%)	474 (33.0%)
Pts w. Grade 3/4/5 AE	899 (61.5%)	1047 (72.9%)
Pts w. Grade 5 AE (Outcome Death)	5 (0.3%)	8 (0.6%)
Pts who Disc. Bev Treatment due to AE	3 (0.2%)	317 (22.1%)
Pts who Disc. Trial Treatment due to AE	84 (5.7%)	343 (23.9%)
All Deaths	10 (0.7%)	13 (0.9%)
Deaths not due to Recurrence	6 (0.4%)	8 (0.6%)
AE of Special Interest for Bevacizumab ##:		
Pts w. AE of Special Interest	303 (20.7%)	829 (57.7%)
Pts w. AE of Special Interest Grade 3/4/5	105 (7.2%)	362 (25.2%)
Pts w. Serious AE of Special Interest	35 (2.4%)	53 (3.7%)
Pts w. Bleeding	29 (2.0%)	169 (11.8%)
Pts w. Congestive Heart Failure	83 (5.7%)	112 (7.8%)
Pts w. Abscesses and Fistulae	3 (0.2%)	3 (0.2%)
Pts w. Gastrointestinal Perforations	2 (0.1%)	13 (0.9%)
Pts w. Hypertension	163 (11.2%)	574 (40.0%)
Pts w. PRES	0 (0.0%)	0 (0.0%)
Pts w. Proteinuria	9 (0.6%)	96 (6.7%)
Pts w. Arterial Thromboembolic Events	6 (0.4%)	14 (1.0%)
Pts w. Venous Thromboembolic Events	34 (2.3%)	30 (2.1%)
Pts w. Wound Healing Complication	15 (1.0%)	44 (3.1%)

#,## AE onset between time of very first drug intake and 18 months plus 28 days

Program : $PROD/cdp10044/bo20906/sae_11.sas
Output : $PROD/cdp10044/i20906a/reports/sae_11_S001_NALL.lst
24JAN2014 17:35 Page 1 of 1

CONCLUSIONS

The primary objective of study BO20906 was not met. Bevacizumab when combined with chemotherapy plus trastuzumab and continued for a treatment duration of one year did not prolong IDFS in the adjuvant treatment of HER2-positive node positive or high risk node-negative breast cancer.

Bevacizumab in combination with chemotherapy and trastuzumab in the adjuvant setting resulted in:

- No difference in IDFS between the Chemo+H+Bv and Chemo+H arms (HR 0.99, 95% CI [0.79; 1.25], p=0.9610).
- No difference between the two treatment arms in the secondary objectives of disease-free survival, overall survival (interim analysis), recurrence-free interval or distant recurrence-free interval as well as for the U.S. definition of IDFS.

- A lack of treatment effect on IDFS in most of the subgroups analyzed that was generally consistent with that of the overall study population.

Overall, no new or unexpected safety signals were observed when compared with the established safety profile of bevacizumab in other cancer indications, including breast cancer, and with the known toxicities of trastuzumab and the chemotherapy regimens used in this study.

The safety analyses showed:

- Higher rates of Grade ≥ 3 AEs, SAEs, and AEs leading to study drug discontinuation in the Chemo+H+Bv arm than in the Chemo+H arm, mainly driven by the known bevacizumab related events.
- A similarly low rate of fatal AEs reported in both treatment arms.
- A cardiac safety profile consistent with that observed in prior studies.
- An overall safety profile consistent with other studies of bevacizumab in breast cancer patients with no new or unexpected toxicities seen.

Batch details
Study BO20906

Product Name	Batch Number
Bevacizumab 400mg	703976
Bevacizumab 400mg	755462
Bevacizumab 400mg	755474
Bevacizumab 400mg	762145
Bevacizumab 400mg	762146
Bevacizumab 400mg	781040
Bevacizumab 400mg	800076
Bevacizumab 400mg	815836
Bevacizumab 400mg	B5025
Bevacizumab 400mg	B6007
Bevacizumab 400mg	B2001
Bevacizumab 400mg	B2016
Bevacizumab 400mg	B3349
Bevacizumab 400mg	B3387
Bevacizumab 400mg	B5011B01
Bevacizumab 400mg	B5011B02
Bevacizumab 400mg	B5017
Bevacizumab 400mg	B5018
Bevacizumab 400mg	B5020
Bevacizumab 400mg	B5021
Bevacizumab 400mg	B5023
Bevacizumab 400mg	B5025
Bevacizumab 400mg	B5027
Bevacizumab 400mg	B6004
Bevacizumab 400mg	B6005
Bevacizumab 400mg	B6007
Bevacizumab 400mg	B6014

Please note, that the IMP Bevacizumab 25 mg/ml is available in two formulations (vial with 100 mg/4 ml and vial with 400 mg/16 ml). In the BO20906 study only Bevacizumab 400 mg/16 ml was used, although both presentations had been authorized.

Product Name	Batch Number
Trastuzumab 150mg	B1341
Trastuzumab 150mg	B1569
Trastuzumab 150mg	B2085
Trastuzumab 150mg	B2089
Trastuzumab 150mg	B2091
Trastuzumab 150mg	B1341
Trastuzumab 150mg	B1372
Trastuzumab 150mg	B1440
Trastuzumab 150mg	B1559
Trastuzumab 150mg	B1561
Trastuzumab 150mg	B1569
Trastuzumab 150mg	B1574
Trastuzumab 150mg	B1578
Trastuzumab 150mg	B1579
Trastuzumab 150mg	B1581
Trastuzumab 150mg	B1586
Trastuzumab 150mg	B2085
Trastuzumab 150mg	B2086
Trastuzumab 150mg	B2088
Trastuzumab 150mg	B2089
Trastuzumab 150mg	B2091
Trastuzumab 150mg	B2096
Trastuzumab 150mg	B2097
Trastuzumab 150mg	B2098
Trastuzumab 150mg	B2099
Trastuzumab 150mg	H0724
Trastuzumab 150mg	H0738

Product Name	Batch Number
Docetaxel 20mg	D0A143/D0A141
Docetaxel 80mg	D0A152/D0A142
Docetaxel 80mg	D0C308/D0C300
Docetaxel 20mg	D7D757/D7D758
Docetaxel 80mg	D7D759/D7D760
Docetaxel 80mg	D7D759/D8C545
Docetaxel 20mg	D8C543/D8C541
Docetaxel 20mg	D8C543/D8C675
Docetaxel 80mg	D8C547/D8C545
Docetaxel 80mg	D8C547/D9A362
Docetaxel 80mg	D8C548/D8C545
Docetaxel 80mg	D8C718/D8C676
Docetaxel 20mg	D8C757/D8C675
Docetaxel 20mg	D9A001/D8C675
Docetaxel 80mg	D9A274/D9A362
Docetaxel 20mg	D9A361/D9A110
Docetaxel 20mg	D9C465/D9C463
Docetaxel 80mg	D9C467/D9C464

List of Amendments

Study BO20906

Protocol Amendments

This summary reflects the changes made from the February 1, 2008 version (Version 1) of the CIRG (TRIO) 011 / NSABP B-44-I / BO20906 protocol to the version dated May 6, 2009 (Version 2).

Many of the revisions made in Amendment #1 were for the purpose of providing clarifications, instructions for consistency with CRF completion guidelines, and minor corrections that were identified during the first year after study activation.

Amendment #1 changes of greater significance include the following:

- At the investigator's discretion, expansion of tissue expanders can continue during bevacizumab therapy. Instructions regarding the minimum time required for replacing the expander with a permanent breast implant have been provided.
- The option of using PET-CT scan as a substitute for CT and PET scans has been provided.
- An additional option for proteinuria testing has been provided. UPC ratio may be used for proteinuria screening and as a follow-up test after a dipstick reading of ≥ 2. Instructions for calculation of UPC ratio have been provided.
- Text has been added to specify that patients with synchronous or metachronous contralateral in situ breast cancers are eligible.
- The LVEF assessment schedule has been revised to make the assessments more consistent between Groups 1A/1B and 2A/2B. Specifically, the assessments at 8, 15, and 24 months after randomization have been changed to 7, 10, and 18 months following randomization.
- Instructions have been addressed for reporting the LVEF as a whole number when the cardiac imaging facility provided the LVEF with a decimal point or as a range.
- The definition of grade 1 LVEF decrease for the BETH Trial has been added.
- Acceptable timeframes for follow-up visits, testing, and specimen collections were added to the study schedules to allow added flexibility following completion of therapy.
- Hypertension assessment and related bevacizumab treatment instructions have been provided to enhance the accuracy of BP assessments and to address treatment decisions when elevated BP is detected on the treatment day.
- Improved instructions and a tool (dosing graphs) have been provided to illustrate the duration of targeted therapy and number the maximum number of targeted therapy doses.
- Additional instructions have been added to improve the clarity and consistency of the carboplatin dose calculations. Related to this, a recommendation has also been added for adjustment of the creatinine value (for use in the Cockcroft-Gault formula) if the lab performing creatinine testing utilizes Isotope Dilution Mass Spectrometry (IDMS)-traceable calibration methods.
- When appropriate, instructions for supportive therapies, such as dexamethasone, G-CSF, fluoroquinilones, and erythropoiesis-stimulating agents have been updated and clarified to allow investigators to follow their usual clinical management practices.
- Instructions regarding the documentation requirements for cancer recurrence have been provided in greater detail.

List of Study Sites
Study BO20906

Listing of Investigators by Site

Protocol : BO20906

Sites: All sites that have enrolled a patient

Site #	Center
123972	Universitätsklinikum Erlangen; Frauenklinik, Universitätsstraße 21-23, 91054, Erlangen, GERMANY
123973	Friedrich-Schiller-Uni Jena; Klinik für Frauenheilkunde & Geburtshilfe, Bachstraße 18, 07740, Jena, GERMANY
123974	HSK Dr.-Horst-Schmidt-Kliniken; Klinik für Gynäkologie und gynäkologische Onkologie, Ludwig-Erhard-Str. 100, Station A52, room 19/20, 65199, Wiesbaden, GERMANY
123975	Rotkreuzklinikum München; Frauenklinik, Taxisstrasse 3, 80637, Muenchen, GERMANY
123977	KLINIK SCHAUMBURG, KREISKRANKENHAUS; GYNAEKOLOGIE & GEBURTSHILFE, AM KREISKRANKENHAUS 1, 31655, STADTHAGEN, GERMANY
123978	HOCHWALDKRANKENHAUS, Chaumont Platz 1, 61231, Bad Nauheim, GERMANY
123979	JOHANNITER-KRANKENHAUS GENTHIN-STENDAL; KLINIK FÜR FRAUENHEILKUNDE & GEBURTSHILFE, Bahnhofstraße 24-26, 39576, Stendal, GERMANY
123981	Klinikum der Johann Wolfgang von Goethe Universität, Frauenklinik, Theodor-Stern-Kai 7, 60596, Frankfurt, GERMANY
123982	Asklepios Klinik; Abt. Gynäkologie und Geburtshilfe, Goethestrasse 4, 35423, Lich, GERMANY
123985	Gesundheitszentrum St. Marien GmbH; Med. II, Hämatologie/Onkologie, Mariahilfbergweg 7, 92224, Amberg, GERMANY
123987	St. Vincenz-Elisabeth-Hospital; Katholisches Klinikum Mainz; Frauenklinik, An der Goldgrube 11, 55131, Mainz, GERMANY
123990	CLINICA ONCOLOGICA DE ROSARIO, Córdoba 2457 . CP S2000KZE, S2000DSK, Rosario, ARGENTINA
123991	Policlinica Privada Site la Plata SA; Oncology, Avenida 7 nº 505, B1902CMK, La Plata, ARGENTINA
123993	Mount Medical Center, 146 MOUNTS BAY ROAD, 6000, PERTH, Western Australia, AUSTRALIA
123994	SOUTHERN MEDICAL DAY CARE; CLINICAL TRIALS UNIT, 410 CROWN STREET, 2500, WOLLONGONG, New South Wales, AUSTRALIA
123996	Royal Brisbane and Women's Hospital (RBWH); ONCOLOGY DEPARTMENT, Butterfield Street, 4029, BRISBANE, Queensland, AUSTRALIA
123997	Ashford Cancer Center Research, 520 South Road, Tennyson Centre, 520 South Road, 5037, Kurralta Park, South Australia, AUSTRALIA
123999	ALFRED HOSPITAL; MEDICAL ONCOLOGY, COMMERCIAL ROAD, 3181, MELBOURNE, Victoria, AUSTRALIA

124002 PRIVATE PRACTICE, PA, 6400 W Newberry Rd, SUITE 208, Gainsville, FL, 32605, UNITED STATES

124003 CANCER CARE CENTER, INC., 2210 GREEN VALLEY ROAD, SUITE 1, NEW ALBANY, IN, 47150, UNITED STATES

124004 überörtl. Mammazentrum Hamburg Schlotfeldt, Frauenthal 7, 20149, Hamburg, GERMANY

124005 HOSPITAL BRITANICO; ONCOLOGIA, Perdriel 74, 2nd Floor, office # 61, Servicio de Oncologia, C1280AEB, Buenos Aires, ARGENTINA

124007 UAB COMPREHENSIVE CANCER CENTER, 1824 6TH AVENUE SOUTH, WALLACE TOWER INSTITUTE, BIRMINGHAM, AL, 35294-3300, UNITED STATES

124009 UNI OF TENNESSEE CANCER INST., 1331 UNION AVENUE, SUITE 800, MEMPHIS, TN, 38104, UNITED STATES

124010 TEXAS CANCER ASSOCIATES, 8220 WALNUT HILL LANE, SUITE 600, DALLAS, TX, 75231, UNITED STATES

124011 AUGUSTA ONCOLOGY ASSOCIATES, 1348 WALTON WAY, SUITE 4300, AUGUSTA, GA, 30901, UNITED STATES

124012 MCLEOD CANCER AND BLOOD CENTER, 310 N. STATE OF FRANKLIN ROAD, SUITE 401, JOHNSON CITY, TN, 37604, UNITED STATES

124015 CANCER SPECIALISTS OF TIDEWATER, 110 WIMBLEDON SQUARE, SUITE E, CHESAPEAKE, VA, 23320, UNITED STATES

124016 BETH ISRAEL MEDICAL CENTER, 10 Nathan D. Perlman Place, New York, NY, 10003, UNITED STATES

124019 Carolina Oncology Specialists, PA - Hickory, 2406 Century Place, SE, Hickory, NC, 28602, UNITED STATES

124020 Mercy Medical Center; Medical Oncology & Hematology, 227 St. Paul Place, 4th Floor, Baltimore, MD, 21202, UNITED STATES

124022 Cone Health Cancer Center, 501 NORTH ELAM AVENUE, GREENSBORO, NC, 27403, UNITED STATES

124025 FRANKSTON HOSPITAL; ONCOLOGY/HAEMATOLOGY, HASTINGS ROAD, 3199, FRANKSTON, Victoria, AUSTRALIA

124026 ST GEORGE HOSPITAL; CANCER CARE CENTRE, 1 SHORT STREET, 2217, SYDNEY, New South Wales, AUSTRALIA

124027 FLINDERS MEDICAL CENTER; MEDICAL ONCOLOGY, FLINDERS DRIVE, 5041, ADELAIDE, South Australia, AUSTRALIA

124028 SHARP HEALTHCARE; ONCOLOGY RESEARCH PROGRAM, 7901 Frost Street, San Diego, CA, 92123, UNITED STATES

124031 North County Oncology, 3617 Vista Way, Suite C, Oceanside, CA, 92056-4506, UNITED STATES

124032 CENTRAL GEORGIA HEMATOLOGY ONCOLOGY ASSOCIATES, 1062 FORSYTH STREET, SUITE 1B, MACON, GA, 31201, UNITED STATES

124033 WEST CLINIC, 100 N Humphreys Blvd, Memphis, TN, 38120, UNITED STATES

124034 UPSTATE NY CANCER RESEARCH & EDUCATION FOUNDATION, 211 WHITE SPRUCE BLVD, ROCHESTER, NY, 14623, UNITED STATES

124036 UNI OF TEXAS - MD ANDERSON CANCER CENTER; DEPT OF BREAST MEDICAL ONCOLOGY, 1155 Pressler Street, BOX 424, Houston, TX, 77030, UNITED STATES

124037 Aptium Oncology, 21020 STATE ROAD 7, BOCA RATON, FL, 33428, UNITED STATES

124038 ASSOCIATES IN ONCOLOGY/HEMATOLOGY P.C., 9707 Medical Center Dr, SUITE 300, Rockville, MD, 20850, UNITED STATES

124039 St. Luke's Mountain States Tumor Inst., 100 East Idaho Street, Boise, ID, 83712, UNITED STATES

124040 NORTHWEST ONCOLOGY/ HEMATOLOGY ASSOC., 8170 ROYAL PALM BLVD, CORAL SPRINGS, 33065-5701, UNITED STATES

124041 HEMATOLOGY & ONCOLOGY OF NORTHEAST GEORGIA, PC, 3320 OLD JEFFERSON ROAD, BLDG. 700, ATHENS, GA, 30607, UNITED STATES

124042 Grand Hôpital De Charleroi, Site Notre Dame; Oncology, 3 Grandrue, B6000, Charleroi, BELGIUM

124044 MEDISCH INSTITUUT ST. AUGUSTINUS; ONCOLOGY, OOSTERVELDLAAN 24, CTO departement, 2610, WILRIJK, BELGIUM

124045 A.Z. KLINA, AUGUSTIJNSLEI 100, 2930, BRASSCHAAT, BELGIUM

124049 UMHAT Tsaritsa Yoanna - ISUL; Clinic of Oncotherapy, 8 BJALO MORE STREET, 1527, SOFIA, BULGARIA

124051 FSBI Research Oncology Institute n.a. N.N.Petrov of Ministry of Health of Russian Federation, Persochny , Leningradskaya Str., bld. 68, 197758, Saint-Petersburg, RUSSIAN FEDERATION

124053 Republican Clinical Oncologic Dispensary of Republic Of Tatarstan, SIBIRSKY TRACT, 29, 420029, KAZAN, RUSSIAN FEDERATION

124056 ST. PETERSBURG ONCOLOGY HOSPITAL, BERESZOVAYA ALLEYA 3/5, 197022 ST PETERSBURG, RUSSIAN FEDERATION

124057 Papageorgiou General Hospital; Medical Oncology, Ring Road of Thessaloniki, Nea Efkarpia, 56429, Thessaloniki, GREECE

124060 HOPITAL SAINT ANTOINE; SCE ONCOLOGIE, 184 Rue Du Faubourg Saint Antoine, 75571, PARIS, FRANCE

124061 IPO do Porto; Servico de Oncologia Medica, RUA DR. ANTONIO BERNARDINO DE ALMEIDA, 4200-319, PORTO, PORTUGAL

124063 NOTTINGHAM CITY HOSPITAL; ONCOLOGY, Hucknall Road, HAYWOOD HOUSE, Nottingham, NG5 1PB, UNITED KINGDOM

124064 CH Dptal Les Oudairies; Hematologie Oncologie, Boulevard Stephane Moreau, 85925, La Roche Sur Yon, FRANCE

124065 BRISTOL ONCOLOGY CENTRE; CLINICAL TRIALS UNIT; R & D department, Grange Road Uphill, Weston Super Mare, BS23 4TQ, UNITED KINGDOM

124067 IPSWICH HOSPITAL; CLINICAL ONCOLOGY, HEATH ROAD, IPSWICH, IP4 5PD, UNITED KINGDOM

124068 CLINIQUE HENRY HARTMANN; Institut d`ONCOLOGIE, 4 rue Kléber, 92300 Levallois-Perret, France

124072 ROYAL BOURNEMOUTH GENERAL HOSPITAL; ONCOLOGY, NHS Foundation Trust Castle Lane East, Bournemouth, BH7 7DW, UNITED KINGDOM

124074 PETERBOROUGH CITY HOSPITAL; ONCOLOGY WARD, Edith Cavell Campus; Bretton Gate, PETERBOROUGH, PE 3 9GZ, UNITED KINGDOM

124076 ROYAL CORNWALL HOSPITAL; DEPT OF CLINICAL ONCOLOGY, CHY HOWLEK (SUNRISE BUILDING), TRURO, TR1 3LJ, UNITED KINGDOM

124078 KRANKENHAUS DER STADT WIEN-HIETZING; ABT. FÜR GYNÄKOLOGIE U. GEBURTSHILFE, WOLKERSBERGENSTRASSE 1, 1130, WIEN, AUSTRIA

124080 LKH SALZBURG - Universitätsklinikum der PMU; III. MEDIZINISCHE ABT., Müllner Hauptstrasse 48, 5020, Salzburg, AUSTRIA

124081 LHK VÖCKLABRUCK; II. INTERNE ABT., Dr. Wilhelm-Bock-Strasse 1, 4840, Vöcklabruck, AUSTRIA

124084 UNIVERSITÄTSKLINIK FÜR FRAUENHEILKUNDE; KLINIK FÜR GYNÄKOLOGIE IV, WÄHRINGER GÜRTEL 18-20, 1090, WIEN, AUSTRIA

124085 LKH-UNIV. KLINIKUM GRAZ; KLINIK FÜR GYNÄKOLOGIE, AUENBRUGGERPLATZ 15, 8036, GRAZ, AUSTRIA

124086 CENTRE CATHERINE DE SIENNE; CHIMIOTHERAPIE, 2 RUE ERIC TABARLY, 44202, NANTES, FRANCE

124087 TIROLER LANDESKRANKENANSTALTEN GES.M.B.H.; ABT. FÜR GYNÄKOLOGIE, ANICHSTRASSE 35, 6020, INNSBRUCK, AUSTRIA

124088 KH DER BARMHERZIGEN SCHWESTERN; NEUROLOGISCHE ABT., ELANGGASSE 16, 4010, LINZ, AUSTRIA

124089 UNIVERSITÄTSKLINIK FÜR INNERE MEDIZIN I; ABT. INNERE MEDIZIN I., WÄHRINGER GÜRTEL 18-20, 1090, WIEN, AUSTRIA

124090 KLINIKUM KREUZSCHWESTERN WELS; III. INTERNE ABT., GRIESKIRCHNERSTRASSE 42, 4600, WELS, AUSTRIA

124091 A.Ö. BEZIRKSKRANKENHAUS KUFSTEIN; INNERE MEDIZIN X, Endach 27, 6330, KUFSTEIN, AUSTRIA

124093 LION'S GATE HOSPITAL, 231 EAST 15TH STREET, Suite 270, V7L 2L7, NORTH VANCOUVER, British Columbia, CANADA

124094 CROSS CANCER INSTITUTE ; DEPT OF MEDICAL ONCOLOGY, 11560 UNIVERSITY AVENUE, T6G 1Z2, EDMONTON, Alberta, CANADA

124095 Hopital Louis Pasteur; Medecine B, 39 Avenue De La Liberte, 68024, Colmar, FRANCE

124100 HOPITAL DU SACRE COEUR DE MONTREAL; ONCOLOGY, 5400 BOUL. GOUIN OUEST, H4J 1C5, MONTREAL, Quebec, CANADA

124102 William Osler Health System Brampton Civic Hospital, 2100 Bovaird Drive East, L6R 3J7, Brampton, Ontario, CANADA

124104 HUMBER RIVER HOSPITAL, 200 Church Street, Weston, M9N 1N8, Toronto, Ontario, CANADA

124105 SOUTHLAKE REGIONAL HEALTH CENTER; COMMUNITY CARE CLINIC / ONCOLOGY, 596 DAVIS DRIVE, L3Y 2P9, NEWMARKET, Ontario, CANADA

124107 ST. MICHAEL'S HOSPITAL, 30 Bond Street, B1 002, M5B 1W8, TORONTO, Ontario, CANADA

124108 University Health Network; Princess Margaret Hospital; Medical Oncology, 610 University Ave, Room 4-115, Suite 5-222, M5G 2M9, Toronto, Ontario, CANADA

124110 WINDSOR REGIONAL CANCER CENTRE, 2220 Kildare Road, N8W 2X3, Windsor, Ontario, CANADA

124111 Institut Daniel Hollard, 12 Rue Docteur Calmette, 38000, Grenoble, FRANCE

124113 HUC; Servico de Ginecologia A, AVDA. DR. BISSYA BARRETO, 3000-075, COIMBRA, PORTUGAL

124114 ST VINCENT'S UNI HOSPITAL; MEDICAL ONCOLOGY, ELM PARK, DUBLIN, 4, IRELAND

124115 Beaumont Hospital; Cancer Clinical Trials Unit, BEAUMONT ROAD, PO Box 1297, DUBLIN, 9, IRELAND

124118 ST. JAMES HOSPITAL; ONCOLOGY, JAMES' STREET, DUBLIN, 8, IRELAND

124119 ST. VINCENT'S WARD MATER MISERICORDIAE HOSP. & MATER PRIV. HOSP., ECCLES STREET, DUBLIN, 7, IRELAND

124120 MERCY UNI HOSPITAL; DEPARMENT OF MEDICAL ONCOLOGY, GRENVILLE PLACE, CORK, IRELAND

124121 OSPEDALE MATER SALUTIS; DEPT OF ONCOLOGY, VIA GIANELLA 1, 37045, LEGNAGO, Lombardia, ITALY

124122 OSPEDALE S.S. TRINITÀ NUOVO; DIVISIONE ONCOLOGIA, LOCALITÀ SAN MARCIANO, 03039, SORA, Lazio, ITALY

124124 IRCCS Istituto Nazionale Tumori Fondazione Pascale; Oncologia Medica A, Via Mariano Semmola, 80131, Napoli, Campania, ITALY

124125 Ospedale Calvi di Noale; U.O. Complessa di Oncologia ed Ematologia Oncologica, Largo San Giorgio, 2, 30035, Mirano, Veneto, ITALY

124126 CENTRO CATANESE DI ONCOLOGIA; ONCOLOGIA MEDICA, VIA DA BORMIDA 64, 95100, CATANIA, Sicilia, ITALY

124129 AZIENDA OSPEDALIERO UNIVERSITARIA DI SASSARI;ONCOLOGIA, VIALE S. PIETRO 8, 07100, SASSARI, Sardegna, ITALY

124130 OSPEDALE S. VINCENZO; ONCOLOGIA MEDICA, Contrada Sirina, 98030, Taormina, Sicilia, ITALY

124132 POLICLINICO OSPEDALIERO SS ANNUNZIATA; U.O. DI CLINICA ONCOLOGICA, VIA DEL VESTINI, 66100, CHIETI, Abruzzo, ITALY

124133 OSPEDALE VITO FAZZI; DIV. ONCOEMATOLOGIA, PIAZZA FILIPPO MURATORE, 73100, LECCE, Puglia, ITALY

124134 IRCCS Ospedale Casa Sollievo Della Sofferenza; Oncologia, VIALE CAPPUCCINI, 71013, SAN GIOVANNI ROTONDO, Puglia, ITALY

124135 AZ. OSP. S. ORSOLA MALPIGHI; ISTITUTO DI ONCOLOGIA SERAGNOLI, 15 VIA ALBERTONI, 40138, BOLOGNA, Emilia-Romagna, ITALY

124143 CLINIQUE CHENIEUX; ONCOLOGY, 18 Rue Du General Catroux, 87039, Limoges, FRANCE

124146 POLYCLINIQUE DU PARC; ONCOLOGIE MEDICALE, 105 RUE ACHILLE VIADIEU, 31078, TOULOUSE, FRANCE

124148 CENTRE PAUL STRAUSS; ONCOLOGIE MEDICALE, 3 RUE DE LA PORTE DE L'HOPITAL, 67065, STRASBOURG, FRANCE

124149 HOPITAL JEAN MINJOZ; Oncologie, 3 Boulevard Alexander Fleming Niveau 1, Cedex, 25030, Besancon, FRANCE

124150 HOTEL DIEU; HEMATOLOGIE- ONCOLOGIE, 1 place du Parvis Notre-Dame, 75004 Paris, FRANCE

124151 HOPITAL MORVAN; ONCOLOGIE - RADIOTHERAPIE, 5 AVENUE DU MARECHAL FOCH, 29609, BREST, FRANCE

124152 Semmelweis Egyetem, Altalanos Orvostudomanyi Kar I. sz. Belgyogyaszati Klinika Onkologiai Reszleg, Tomo u. 25-29, 1083, Budapest, HUNGARY

124153 DEBRECENI EGYETEM ORVOS ES EGESZSEGTUDOMANYI CENTRUM; ONKOLOGIAI TANSZEK, NAGYERDEI KRT. 98, 4032, DEBRECEN, HUNGARY

124165 NATIONAL CANCER INST., 268/1 RAMA VI ROAD, RAJATHEVEE, 10400, BANGKOK, THAILAND

124166 CHULALONGKORN HOSPITAL; MEDICAL ONCOLOGY, RAMA IV ROAD, PATUMWAN, 10400, BANGKOK, THAILAND

124167 PRINCE OF SONGKLA UNI ; UNIT OF MEDICAL ONCOLOGY, PRINCE OF SONGKLA UNIV; UNIT OF MED ONC, HATYAI, 90110, SONGKHLA, THAILAND

124170 Clinic of Oncology - Clinical Center University of Sarajevo, BOLNICKA 25, 71000, SARAJEVO, BOSNIA AND HERZEGOVINA

124172 NATIONAL HOSPITAL; ONCOTHERAPY DEPT, Roth Avenue, 9301, Bloemfontein, SOUTH AFRICA

124173 University of Witwatersrand/Johannesburg Hospital; Dept. of ocnology, 7 York Road, PARKTOWN, 2193, Johannesburg, SOUTH AFRICA

124174 CHINESE ACADEMY OF MEDICAL SCIENCE; CANCER INST. & HOSPITAL, 17 PAN JIA GARDEN, CHAOYANG DISTRICT, 100021, BEIJING, CHINA

124175 307 Hospital of The Chinese PLA; The First Medical Dept of Oncology Dept, No.8, East street, Fengtai District, Beijing, 100071, Beijing, CHINA

124176 The First Affiliated Hospital of Soochow University, No.188 Shizi Street, 215004, Suzhou, CHINA

124177 QUEEN ELIZABETH HOSPITAL; CLINICAL ONCOLOGY, 30 Gascoigene Road, Hong Kong, CHINA

124178 The 81st Hospital of P.L.A., No.34, 34 Biao, Yanggongjing, Nanjing, Nanjing, CHINA

124179 Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech, 1095 Jie Fang Da Dao, 430030, Wuhan, CHINA

124180 TRI-SERVICE GENERAL HOSPITAL; HEMATOLOGY AND ONCOLOGY, NO.325, SEC.2, CHENGGONG RD., NEIHU DISTRICT, 114, TAIPEI, TAIWAN

124181 KOO FOUNDATION SUN YAT-SEN CANCER CENTER; HEMATO-ONCOLOGY, 125 LIH-DER RD., PEI-TOU DISTRICT, 112, TAIPEI, TAIWAN

124182 NATIONAL CHENG KUNG UNI HOSPITAL; DEPT OF HEMATOLOGY & ONCOLOGY, 138 SHENG-LI ROAD, 704, TAINAN, TAIWAN

124183 CHANG GUNG MEDICAL FOUNDATION - LINKOU; DEPT OF SURGERY, 5, FU-Hsin Street, Kweishan, 333, Taoyuan, TAIWAN

124185 CHANGHUA CHRISTIAN HOSPITAL; DEPT OF SURGERY, 135 NANSHIAU STREET, 500, CHANGHUA, TAIWAN

124187 NATIONAL TAIWAN UNI HOSPITAL; DEPT OF ONCOLOGY, 7, Chung-Shan South Road, 100, Taipei, TAIWAN

124188 VETERANS GENERAL HOSPITAL; Department of General Surgery, 201 SHIH-PAI ROAD SECTION 2, 00112, TAIPEI, TAIWAN

124189 SEOUL NATIONAL UNI HOSPITAL; DEPT. OF INTERNAL MEDICINE/HEMATOLOGY/ONCOLOGY, 101, Daehak-ro, Jongno-gu, 110-744, Seoul, KOREA, REPUBLIC OF

124190 SAMSUNG MEDICAL CENTRE; DIVISION OF HEMATOLOGY/ONCOLOGY, 81, Irwon-ro, Gangnam-gu, 135-710, Seoul, KOREA, REPUBLIC OF

124191 ASAN MEDICAL CENTER, UNI ULSAN COLLEGEMEDICINE; DEPT.INTERNAL MEDICINE / DIVISIONHEMATOLOGY/ONCOLOGY, 88, Olympic-ro 43-gil, Songpa-gu, 138-736, Seoul, KOREA, REPUBLIC OF

124192 YONSEI UNI COLLEGE OF MEDICINE, SEVERANCE HOSPITAL; INTERNAL MEDICINE DEPT., 134 Shinchon-Dong, CPO BOX 8044, 120-752, Seoul, KOREA, REPUBLIC OF

124193 BUNDANG SEOUL UNI HOSPITAL; MEDOCAL ONCOLOGY, 82, Gumi-ro 173-gil, Bundang-gu, Seongnam-si, 463-802, Bundang City, KOREA, REPUBLIC OF

124194 ZAKLAD OPIEKI ZDROWOTNEJ MSWIA; ODDZIAL CHEMIOTERAPII, AL. WOJSKA POLSKIEGO 37, 10-228, OLSZTYN, POLAND

124195 CENTRUM ONKOLOGII - INST.IM. MARII SKLODOWSKIEJ-CURIE; KLINIKA NOWOTWOROW PLUCA I KLATKI PIERSIOWEJ, UL. ROENTGENA 5, 02-781, WARSZAWA, POLAND

124197 Bialostockie Centrum Onkologii; Oddzial Onkologii Klinicznej, UL. OGRODOWA 12, 15-027, BIALYSTOK, POLAND

124198 CENTRUM ONKOLOGII, INST.IM M. CURIE-SLODOWSKIEJ; KLINIKA ONKOLOGII KLINICZNEJ, WYBRZEZE ARMII KRAJOWEJ 15, 44-101, GLIWICE, POLAND

124199 Olsztyński Ośrodek Onkologiczny Kopernik sp. z o.o., UL. KOPERNIKA 30, 10-513, OLSZTYN, POLAND

124201 Clinical Hospital Centre Zagreb, Kispaticeva 12, 10000, Zagreb, CROATIA

124205 UNI HOSPITAL FOR TUMOURS; DEPT OF MEDICAL ONCOLOGY, ILLICA 197, 10000, ZAGREB, CROATIA

124206 UNI HOSPITAL SPLIT; ONCOLOGY & RADIOTHERAPY, SPINCICEVA 1, 21000, SPLIT, CROATIA

124207 Veterans Memorial Medical Center; Department of General Surgery, 201 SHIH-PAI ROAD SECTION 2, 00112, TAIPEI, Taiwan

124209 CEBU DOCTORS UNIVERSITY HOSPITAL, Rm. 203A, MAB 1, Osmena Boulevard, 6000, CEBU City, PHILIPPINES

124211 HOPELANDS CANCER CENTRE; ONCOLOGY, 28 HOPELANDS ROAD, OVERPORT, 4001, DURBAN, SOUTH AFRICA

124212 Russian Oncology Research Center n.a. N.N. Blokhin Dpt of Clinical Pharmacology and Chemotherapy, KASHIRSKOYE SHOSSE, 24, 115478, MOSCOW, RUSSIAN FEDERATION

124213 HOSPITAL NACIONAL CARLOS ALBERTO SEGUIN ESCOBEDO-ESSALUD; ONCOLOGY & HAEMATHOLOGY, Calle Peral y Ayacucho S/N Cercado - Arequipa, 04001, Arequipa, PERU

124214 HOSPITAL NACIONAL EDGARDO REBAGLIATI MARTINS; ONCOLOGIA, Avenida Edgardo Rebagliati No 490, Piso 8º A, Jesus Maria, 11, Lima, PERU

124215 CLINICAL CENTER BEZANIJSKA KOSA; ONCOLOGY, AUTOPUT BB, 11080, BELGRADE, SERBIA

124216 CLINICAL CENTER NIS; INSTITUTE OF ONCOLOGY, BUL ZORANA DJINDJICA, 18000, NIS, SERBIA

124223 KAPLAN MEDICAL CENTER; ONCOLOGY INST., Bilu Junc., PO BOX 1, 7610001, Rehovot, ISRAEL

124224 CHAIM SHEBA MEDICAL CENTER; ONCOLOGY DEPT, Sheba Medical Center, 52620-00, Ramat Gan, ISRAEL

124225 SOURASKY / ICHILOV HOSPITAL; ONCOLOGY DEPARTMENT, 6 Weitzman Street, 64239-06, Tel Aviv, ISRAEL

124226 CARMEL HOSPITAL; ONCOLOGY UNIT, 7, MICHAL STR., 34362, HAIFA, ISRAEL

124227 Rabin Medical Center; Oncology Dept, Rabin \Belinson M.C,JABOTINSKI 39 Street, PO BOX 85, 49100, PETACH TIKVA, ISRAEL

124228 ASSAF HAROFEH; ONCOLOGY, Assaf Harofe Medical Center, Tsrifin, 70300, ISRAEL

124229 MEIR MEDICAL CENTER; ONCOLOGY, 59 Tschernichovsky, 4428164, Kfar-Saba, ISRAEL

124232 Hospital del Mar; Servicio de Oncologia, Paseo Maritimo 25-29, 08003, Barcelona, BARCELONA, SPAIN

124233 Hospital Ruber Internacional;Servicio de Oncologia, LA MASO 38, 28034, MADRID, MADRID, SPAIN

124234 Hospital Universitario Miguel Servet; Servicio Oncologia, PASEO ISABEL LA CATOLICA 1-3, 50009, ZARAGOZA, ZARAGOZA, SPAIN

124235 Hospital de Terrassa; Servicio de Oncologia, CARRETERA DE TORREBONICA S/N, 08227, BARCELONA, BARCELONA, SPAIN

124236 Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia, C/ Mas Casanovas nº 90, 08041, Barcelona, BARCELONA, SPAIN

124237 Hospital Universitario de Canarias;servicio de Oncologia, Ofra S/N La Cuesta, 38320, La Laguna, TENERIFE, SPAIN

124238 Chi De Creteil; Radiotherapie Oncologie, 40 AVENUE DE VERDUN, 94010, CRETEIL, FRANCE

124240 Hospital de Torrevieja; Servicio de Oncologia, Ctra. CV-95 Partida La Ceñuela, 03186, Torrevieja, ALICANTE, SPAIN

124241 Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Edificio Santa Fe, Planta Principal, Investigación Oncológica, 08208, Sabadell, Barcelona, BARCELONA, SPAIN

124242 Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia, AVDA. DEL EJERCITO ESPANOL S/N, 23007, JAEN, JAEN, SPAIN

124243 Instituto Valenciano Oncologia; Oncologia Medica, C/ Profesor Beltrán Báguena,8, 46009, Valencia, VALENCIA, SPAIN

124244 Hospital Universitario Virgen del Rocio; Servicio de Oncologia, AVENIDA MANUEL SIUROT S.N., 41013, SEVILLA, SEVILLA, SPAIN

124245 Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, PASEO DE SAN VICENTE 182, 37007, SALAMANCA, SALAMANCA, SPAIN

124246 Hospital General Universitario de Elche; Servicio de Oncologia, Hospital de día, 1ªplanta Camí de la Almazara, 11, 03203, ELCHE, ALICANTE, SPAIN

124247 Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, CAMPUS UNIVERSITARIO DE TEATINOS S/N., 29010, Malaga, MALAGA, SPAIN

124248 Centro Oncológico Gallego José Antonio Quiroga y Piñeiro, Servicio de Oncologia, C/ Dr Camilo Veiras s/n, 15009, La Coruña, LA CORUÑA, SPAIN

124249 IInstituto Oncologico de San Sebastian, Oncologikoa; Servicio de Oncologia, Paseo Dr. Beguiristain, 121, Planta primera, 20014, SAN SEBASTIAN, GUIPUZCOA, SPAIN

124250 Hospital de Cabueñes; Servicio de Oncologia, c/ Los Prados 395, 33394, Gijon, ASTURIAS, SPAIN

124252 Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Villarroel 170, 08036, Barcelona, BARCELONA, SPAIN

124254 Hospital Clinico Universitario Lozano Blesa; Servicio de Oncologia, Avenida San Juan Bosco 15, 50009, Zaragoza, ZARAGOZA, SPAIN

124256 Hospital Universitario Clínico San Carlos; Servicio de Oncologia, CALLE PROFESSOR MARTIN LAGOS S/N, 28040, MADRID, MADRID, SPAIN

124257 Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Crta. Del Canyet, s/n, 08916, Barcelona, BARCELONA, SPAIN

124258 Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, BLASCO IBANEZ 17, 46010, VALENCIA, VALENCIA, SPAIN

124259 Fundacion Hospital de Alcorcon; Servicio de Oncologia, C/ Budapest 1, 28922, Alcorcon, MADRID, SPAIN

124260 Complejo Hospitalario Santa Maria Nai- Dr. Cabaleiro; Servicio de Oncologia, RAMÓN PUGA 54, 32005, ORENSE, ORENSE, SPAIN

124261 HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Calle Oña, num. 10., 28050, Madrid, MADRID, SPAIN

124262 Hospital de Barbastro; Servicio de Oncologia, CTRA. NACIONAL 240 S/N, BARBASTRO, 22300, BARBASTRO, HUESCA, SPAIN

124263 Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Oncologia, AVDA. DE FRANÇA, S/N., 17007, GIRONA, GIRONA, SPAIN

124264 Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Oncologia, AVENIDA BARBER 30, 45004, TOLEDO, TOLEDO, SPAIN

124266 Complejo Hospitalario de Pontevedra; Servicio de Oncologia, c/Loureiro Crespo, 2, MOURENTE, 36002, Pontevedra, PONTEVEDRA, SPAIN

124267 Hospital General Universitario de Guadalajara; Servicio de Oncologia, DONANTES DE SANGRE S/N, 19002, GUADALAJARA, GUADALAJARA, SPAIN

124268 Hospital Regional Universitario Carlos Haya, Avda. Carlos Haya 82, 29010, Malaga, MALAGA, SPAIN

124269 CLINICAL HOSPITAL OSIJEK; DEPT FOR ONCOLOGY & RADIOTHERAPY, J. HUTTLERA 4, 31000, OSIJEK, CROATIA

124272 Santa Casa de Misericordia de Porto Alegre, Rua Sarmento Leite, 187 - Centro, 90020-090, Porto Alegre, RS, BRAZIL

124273 Clinica de Oncologia de Porto Alegre - CliniOnco, Rua Dona Laura 226 - Rio Branco, 90430-090, Porto Alegre, RS, BRAZIL

124274 Instituto de Oncologia de Sorocaba - CEPOS, Rua abrao mahuad 140 sala 01, 18030-245, Sorocaba, SP, BRAZIL

124275 Hospital de Caridade de Ijui; Oncologia, AVENIDA DAVID JOSÉ MARTINS 152, 98700-000, Ijui, RS, BRAZIL

124276 Hospital Amaral Carvalho, Rua das Palmeira, 122 - Jau SP, 17210-080, Jau, SP, BRAZIL

124277 Centro Goiano de Oncologia - CGO, Rua 17, Qd K10, Lt 08, # 437, SETOR AEROPORTO, 74140-050, Goiania, GO, BRAZIL

124280 Hospital Vera Cruz, Avenida Barbacena 653, Rua Timbiras 3109 Sala 602, 30190-130, Belo Horizonte, MG, BRAZIL

124281 Hospital Nossa Senhora da Conceicao, Av. Francisco Trein; 596 Sala 24 - 1 andar, 91350-200, Porto Alegre, RS, BRAZIL

124282 Faculdade de Medicina do ABC - FMABC; Centro de Estudos e Pesquisa de Hematologia e Oncologia - Centro de Oncologia do ABC, Avenida Príncipe de Gales, 821 - Anexo III - Vila Príncipe de Gales - CEP: 09060-650 - Santo André-SP, BRAZIL

124287 Philippine General Hospital; Section Of Medical Oncology, Taft Avenue, 1000, Manila, PHILIPPINES

124288 Prince of Wales Hosp; Dept. Of Clinical Onc, 30-32 NGAN SHING STREET, SHATIN, N/A, HONG KONG, CHINA

124289 DR. H. BLISS MURPHY CANCER CENTRE; ONCOLOGY, 300 PRINCE PHILIP DRIVE, A1B 3V6, ST. JOHN'S, Newfoundland, CANADA

124290 CSSS champlain - Charles-Le Moyne, 3120 Taschereau Blvd, J4V 2H1, Greenfield Park, Quebec, CANADA

124292 Complejo Hospitalario Nuestra Señora de la Candelaria; Servicio de Oncologia, CARRETERA DEL ROSARIO S/N, 38010, SANTA CRUZ DE TENERIFE, TENERIFE, SPAIN

124296 University Medical Centre Maribor; Depart. of Gynecology & Breast Oncology, LJUBLJANSKA 5, 2000, MARIBOR, SLOVENIA

124297 COUNTY HOSPITAL ALBA; ONCOLOGY, 23 REVOLUTIEI ST., 510073, ALBA IULIA, ROMANIA

124298 Hadassah Ein Kerem Medical Center, POB 12000, Jerusalem, 91120, Israel

124299 ONCOSALUD SAC; ONCOLOGÍA, GUARDIA CIVIL 585 LIMA 41, SAN BORJA, 41, LIMA, PERU

124302 Hospital das Clinicas - UFRGS, RUA RAMIRO BARCELOS 2350 - 2 ANDAR - PREDIO 21, Centro de Pesquisa Clínica - 3o floor - room 21307, 90035-003, Porto Alegre, RS, BRAZIL

124304 Karolinska University Hospital; Department of General Oncology, Sodersjukhuset, 11883, Stockholm, SWEDEN

124305 Ziv Medical Center; Oncology Department, HaRambam Road, POB 1008, 13100, Sefad, ISRAEL

124306 Wojewódzki Szpital Specjalistyczny Nr 3, Energetyków 46, 44-200, Rybnik, POLAND

124307 SAHLGRENSKA UNIVERSITETSSJUKHUSET; ONKOLOGY, Per Dubbsgatan 15, 413 45, Goteborg, SWEDEN

124308 EASTERN CT HEMA/ONCO ASSOC; DEPT OF ONCOLOGY, 330 WASHINGTON STREET, SUITE 220, NORWICH, CT, 06360, UNITED STATES

124310 ONCOLOGY HEMATOLOGY GROUP OF SOUTH FLORIDA; BAPTIST MEDICAL ARTS BUILDING, 8940 NORTH KENDALL DRIVE, MIAMI, 33176-2197, UNITED STATES

124314 The Center for Cancer and Blood Disorders - Fort Worth, 800 West Magnolia Ave., Fort Worth, TX, 76104, UNITED STATES

124315 Robert-Bosch-Krankenhaus; Interdisziplinäres Zentrum; Tumorzentrum, Auerbachstr. 110, 70376, Stuttgart, GERMANY

124321 Universitätsmedizin Göttingen Georg-August-Universität; Klinik für Gynäkologie und Geburtshilfe, Robert-Koch-Str. 40, 37075, Göttingen, GERMANY

124323 Universitätsklinikum "Carl Gustav Carus"; Frauenheilkunde und Geburtshilfe, Fetscherstr. 74, Haus 21, 01307, Dresden, GERMANY

124324 Klinik Lippe Lemgo; Medizinische Klinik II/Haematoonkologie, RINTELNER STRAßE 85, 32657, LEMGO, GERMANY

124326 Klinikum Chemnitz gGmbH; Frauen- und Kinderklinik, Flemmingstr. 2-4, 09116, Chemnitz, GERMANY

124327 Universitätsklinikum Essen; Zentrum Für Frauenheilkunde, Hufelandstr. 55, 45122, Essen, GERMANY

124329 Onkologische Schwerpunktpraxis, Annenstrasse 11, 267xx, Leer, GERMANY

124330 Krh Klinikum Nordstadt; Frauenklinik, Herrenhaeuser Kirchweg 5, 30167, Hannover, GERMANY

124331 SANA Klinikum Hameln-Pyrmont; Frauenklinik / Brustzentrum, Saint-Maur-Platz 1, 31785, Hameln, GERMANY

124332 Praxis für Onkologie und Hämatologie, Springstraße 24, 456xx, Recklinghausen, GERMANY

124333 LUISENKRANKENHAUS, Degerstraße 8, 40235, Düsseldorf, GERMANY

124335 Klinikum Dortmund gGmbH; Frauenklinik, Beurhausstr. 40, 44137, Dortmund, GERMANY

124336 KREISKRANKENHAUS ROTTAL INN GMBH, KH EGGENFELDEN; GYNÄKOLOGIE & GEBURTSHILFE, SIMONSÖDER ALLEE 20, 84307, EGGENFELDEN, GERMANY

124337 Klinikum St. Georg GmbH; Franziskus-Hospital Harderberg; Klinik für Gynaekologie und Geburtshilfe, Alte Rothenfelder Strasse 23, 49124, Georgsmarienhütte, GERMANY

124338 Universitätsklinikum Münster; Klinik für Frauenheilkunde und Geburtshilfe, Albert-Schweitzer-Campus 1, 48149, Münster, GERMANY

124339 ROYAL NORTH SHORE HOSPITAL; ONCOLOGY, PACIFIC HIGHWAY, ST LEONARD, 2065, ST. LEONARDS, New South Wales, AUSTRALIA

124340 Sharp Chula Vista Medical Center, 751 Medical Center Court, Chula Vista, CA 91911, UNITED STATES

124342 USC Norris Cancer Center, 1441 Eastlake Ave, Los Angeles, 90033, UNITED STATES

124345 PHOEBE CANCER CENTER; HEMATOLOGY/ONCOLOGY, 425 THIRD AVENUE, THE MEDICAL TOWER, SUITE 100, ALBANY, GA, 31701, UNITED STATES

124348 COMPREHENSIVE BLOOD/CANCER CTR, 6501 Truxton Avenue, Bakersfield, CA, 93309, UNITED STATES

124352 TOM BAKER CANCER CENTRE; DEPT OF MEDICINE, 1331 29TH STREET NORTHWEST, T2N 4N2, Calgary, Alberta, CANADA

124353 CHU de Québec – Hôpital du Saint-Sacrement / ONCOLOGY, 1050 Chemin Sainte-Foy, G1S 4L8, Quebec, Quebec, CANADA

124358 Chu D'Amiens, 124 Rue Camille Desmoulins, 80054, Amiens, FRANCE

124360 Oncology Office, 5454 Wisconsin Ave., Suite 1300, Chevy Chase, MD, 20815, UNITED STATES

124362 Medical Oncology and Hematology, 455 Lewis Ave., Suite 102, Meriden, CT, 06451, UNITED STATES

124364 Marshfield Clinic, 1000 North Oak Ave, GR-1, Marshfield, WI, 54449, UNITED STATES

124366 CCOP, Wayne Memorial Hospital / Southeast Cancer Control Consortium Inc, P.O. Box 8001, Goldsboro, NC, 27533, UNITED STATES

124367 Kaiser Permanente - San Diego (Zion Ave), 400 Craven Road, San Marcos, CA, 92078, UNITED STATES

124368 West Michigan Cancer Center, 200 NORTH PARK STREET, KALAMAZOO, MI, 49007, UNITED STATES

124369 SCRANTON HEMATOLOGY ONCOLOGY, 743 JEFFERSON AVENUE, SCRANTON, PA, 18510, UNITED STATES

124370 NORTH IDAHO CANCER CENTER, 700 IRONWOOD DRIVE, COEUR D'ALENE, ID, 83814, UNITED STATES

124372 Wilshire Oncology Medical Group, 8283 Grove Avenue, Suite 207, Rancho Cucamonga, CA, 91730, UNITED STATES

124373 South Georgia Medical Center; Pearlman Cancer Center, 2501 Patterson St., Valdosta, GA, 31602, UNITED STATES

124374 Westpfalz-Klinikum GmbH; Klinik für Frauenheilkunde und Geburtshilfe, Hellmut-Hartert-Str. 1, 67655, Kaiserslautern, GERMANY

124377 McGill University; Montreal General Hosptial; Oncology, 1650 CEDAR AVENUE, ROOM A7-130, H3G 1A4, MONTREAL, Quebec, CANADA

124378 The Ottawa Hospital; Division of Infectious Diseases, 501 Smyth Road, Box 935, K1H 8L6, Ottawa, Ontario, CANADA

124379 John H Stroger Jr Hospital of Cook County; MBCCOP, 1969 West Ogden Avenue, Chicago, IL 60612-3714, UNITED STATES

124380 Oncology Hematology Care, 4350 Malsbary Road, Suite 200, Cincinnati, OH, 45242, UNITED STATES

124382 Sutter Cancer Center, Sacramento, 5275 F STREET, SACRAMENTO, CA, 95819, UNITED STATES

124383 Newark Beth Israel Medical Center, 201 LYONS AVENUE, NEWARK, NJ, 07112, UNITED STATES

124386 CANCER INST. OF NEW JERSEY OF HAMILTON, 2575 KLOCKNER ROAD, HAMILTON, NJ, 08690, UNITED STATES

124389 Kaiser Permanente - Oakland, 3701 Broadway Street, Oakland, CA, 94611, UNITED STATES

124390 KAISER PERMANENTE, 2238 Geary St., SUITE 219, San Francisco, CA, 94115, UNITED STATES

124391 K. Permanente - Santa Clara, 710 Lawrence Expressway, Santa Clara, CA, 95051, UNITED STATES

124392 K. Permanente - S. San Fran, 1200 EL CAMINO REAL, SOUTH SAN FRANCISCO, CA, 94080, UNITED STATES

124393 Kaiser Permanente - Vallejo, 975 SERENO DRIVE, VALLEJO, CA, 94589, UNITED STATES

124394 K. Permanente - Walnut Creek, 1425 South Main Street, Walnut Creek, CA, 94596, UNITED STATES

124395 PARK NICOLLET CLINIC CANCER CENTER, 3850 PARK NICOLLET BLVD, ST LOUIS PARK, MN, 55416, UNITED STATES

124397 NEW YORK ONCOLOGY HEMATOLOGY, P.C., 400 Patroon Creek Blvd, Suite One, Albany, NY, 12206, UNITED STATES

124402 Oncology Care Associates, 6410 Rockledge Drive, Suite 305, Bethesda, MD, 20817, UNITED STATES

124403 NORTHWEST GEORGIA ONCOLOGY CENTERS, 531 Roselan Street NW, SUITE 200, Marietta, GA, 30060, UNITED STATES

124405 West Valley Hematology Oncology The Thomas and Dorothy Leavey Cancer Center, 18300 ROSCOE BLVD, NORTHRIDGE, CA, 91325, UNITED STATES

124406 SANSUM SANTA BARBARA MEDICAL FOUNDATION CLINIC, 301 West Pueblo Street, Santa Barbara, CA, 93105, UNITED STATES

124407 CENTRAL COAST MEDICAL ONCOLOGY, 220 SOUTH PALISADE, SUITE 204, San Luis Obispo, CA, 93454, UNITED STATES

124408 Santa Barbara Hematology Oncology Medical Group, Inc., 540 West Pueblo Street, Santa Barbara, CA, 93105, UNITED STATES

124410 Baton Rouge General Medical Center, 3600 Florida Boulevard, P.O. Box 2511, Baton Rouge, LA, 70806, UNITED STATES

124411 Glens Falls Hospital - C.R. Cancer Center, 102 PARK STREET, GLENN FALLS, NY, 12801, UNITED STATES

124414 LAKELAND REGIONAL CANCER CENTER, 3525 Lakeland Hills Blvd, Lakeland, FL, 33804-1057, UNITED STATES

124415 SCRIPPS CLINICAL RESEARCH CENTER, 11025 North Torrey Pines Road, Suite 200, La Jolla, CA, 92037-1030, UNITED STATES

124416 CANCER CARE OF WNC, 445 BILTMORE AVENUE, ASHEVILLE, NC, 28801, UNITED STATES

124418 PALM BEACH CANCER INST., 1309 N FLAGLER DRIVE, WEST PALM BEACH, FL, 33401, UNITED STATES

124419 Sylvester Comprehensive Cent., 1475 NW 12 Ave, #3510(D8-4), Miami, FL, 33136, UNITED STATES

124420 Marshfield Clinic Weston Center, 3501 Cranberry Boulevard, Weston, WI, 54476, UNITED STATES

124424 Sibley Memorial Hospital, 5255 Loughboro Road, NW, Washington, WA, 20016, UNITED STATES

124425 Florida Cancer Specialists, Sarasota downtown, 1970 GOLF STREET, SARASOTA, FL, 34236, UNITED STATES

124426 Case Western Research University; University Hospitals Case Medical Center, 11100 EUCLID AVENUE, CLEVELAND, OH, 44106-5067, UNITED STATES

124428 Bridgeport Hospital, 267 Grant St., Bridgeport, CT, 06610, UNITED STATES

124431 UCLA / Santa Clarita Valley Cancer Center, 23929 MCBean Parkway, Suite 215 Building F, Valencia, CA, 91355, UNITED STATES

124434 Samaritan North Health Center, 9000 North Main Street, Dayton, OH, 45415, UNITED STATES

124436 Cancer Care Assoc Med Group Inc; Redondo Beach Offices, 415 N. Prospect Ave, 4th Floor, Redondo Beach, CA 90277, United States

124437 Saint Luke's Cancer Institute, Department of Pharmacy, Suite 259, Kansas City, MO, 64111, UNITED STATES

124441 Thompson Cancer Survival Center, 1915 White Avenue, Knoxville, TN, 37916-2305, UNITED STATES

124443 Geisinger Clinic; Breast Clinic Department of General Surgery, 100 North Academy Drive, Danville, PA, 17822, UNITED STATES

124444 Akron General Medical Center, 400 Wabash, Akron, OH, 44307, UNITED STATES

124449 CANCER CARE OF MAINE, 33 Whiting Hill Road, Brewer, ME, 04412, UNITED STATES

124450 Albert Einstein Healthcare Network ; Cancer Center, 5501 OLD YORK ROAD, PHILADELPHIA, PA, 19141, UNITED STATES

124470 Kaiser Permanente - Fontana, 9961 Sierra Avenue, Fontana, CA, 92335, UNITED STATES

124472 Kaiser Permanente - Panorama City, 13652 Cantara Street, Tower Building, Area 301, Panorama City, CA, 91402, UNITED STATES

124473 Kaiser Permanente - Baldwin Park, 1011 Baldwin Park Blvd, Baldwin Park, CA, 91706, UNITED STATES

124474 Kaiser Permanente Los Angeles, 1515 North Vermont, Los Angeles, CA, 90027, UNITED STATES

124477 Baylor College of Medicine, 6620 MAIN STREET, SUITE 1350, HOUSTON, TX, 77030, UNITED STATES

124481 Clearview Cancer Institute, 3601 CCI Dr, Huntsville, AL, 35805, UNITED STATES

124483 Clearview Cancer Institute - Decatur, 310 8th Avenue, Decatur, AL, 35601, UNITED STATES

124485 CCOP, HEMATOLOGY-ONCOLOGY ASSOCIATES OF CNY, 5008 BRITTONFIELD PKY, PO BOX 2050, EAST SYRACUSE, NY, 13057, UNITED STATES

124486 Mcgill University - Royal Victoria Hospital; Oncology, 687 PINE AVENUE, H3A 1A1, MONTREAL, Quebec, CANADA

124487 NORTHEASTERN ONTARIO; REGIONAL CANCER CENTRE, 41 RAMSEY LAKE ROAD, P3E 5J1, SUDBURY, Ontario, CANADA

124489 HOPITAL NOTRE-DAME, 1560 Sherbrooke Street East, H2L4M1, MONTREAL, Quebec, CANADA

124490 THE SIR MORTIMER B. DAVIS GENERAL HOSPITAL, 3755 CHEMIN DE LA COTE STE-CATHERINE, H3T 1E2, MONTREAL, Quebec, CANADA

124492 Lapeer Regional Hospital, McLaren Cancer Institute - Lapeer,1295 Barry Drive, Suite B, Lapeer, MI 48446, UNITED STATES

124494 Edward Cancer Center Plainfield, 24600 W 127th Street, Plainfield, IL, 60585, UNITED STATES

124498 St Mary's Hospital and Medical Center, 750 Wellington Ave, Grand Junction, CO, 81502-1628, UNITED STATES

124503 MATER HOSPITAL; DEPARTMENT OF CANCER SERVICES, Stanley Street, Level 3, 4104, Brisbane, Queensland, AUSTRALIA

124504 Austin Hospital; Medical Oncology, STUDLEY ROAD, 3084, HEIDELBERG, Victoria, AUSTRALIA

124506 Zhejiang Cancer Hospital, No. 38 Guangji Road, Banshan, 310022, Hangzhou, CHINA

124511 POLYCLINIQUE BORDEAUX NORD AQUITAINE; CHIMIOTHERAPIE RADIOTHERAPIE, 15 33 RUE CLAUDE BOUCHER, 33077, BORDEAUX, FRANCE

124513 Institut Claudius Regaud; Departement Oncologie Medicale, 1 avenue Irene Joliot Curie, Cedex 3, 31059, Toulouse, FRANCE

124514 Universitätsmedizin Mainz; Klinik u. Poliklinik f. Geburtshilfe u. Frauenheilkunde, Langenbeckstrasse 1, 55131, Mainz, GERMANY

124515 P.Stradins Clinical University Hospital, Oncology Centre, Pilsonu iela 13, LV-1002, Riga, LATVIA

124516 Centro Oncológico Estatal; ISSSEMYM Oncología, AV. SOLIDARIDAD LAS TORRES; # 101, COLONIA DEL PARQUE, 50180, TOLUCA, MEXICO

124518 CCOP, St. Joseph Mercy Hospital, St. Joseph Mercy Health System, Cancer Center OC-209, P.O. Box 995, 5301 East Huron River Dr., 48106 Ann Arbor, UNITED STATES

124519 Washington Cancer Institute, MedStar Washington Hosp Center, 110 Irving Street NW C2149, Washington, DC, 20010, UNITED STATES

124520 CANCER INST. OF NEW JERSEY, 195 LITTLE ALBANY STREET, NEW BRUNSWICK, NJ, 08901, UNITED STATES

124521 Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca, 34-36 Republicii Str, 400015, Cluj Napoca, ROMANIA

124522 ONCOLOGY INST. CLUJ-NAPOCA; CANCER DEPT, 34-36 Republicii Street, 400015, Cluj-Napoca, ROMANIA

124523 Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología, c/ Xubias de Abaixo sn, 15006, La Coruña, LA CORUÑA, SPAIN

124524 Exempla Lutheran Medical Center; Radiation Oncology, 8300 West 38th Avenue, Wheat Ridge, CO, 80033, UNITED STATES

124531 Penn St. Cancer Inst. At Mt. Nittany Med. Ctr, 1800 E Park Ave, State College, PA, 16803, UNITED STATES

124532 St. John's Regional Health Center, 1730 E. Republic Road, Springfield, MO, 65804, UNITED STATES

124533 Cox Health Systems, 3801 S. National Avenue, Springfield, MO, 65807, UNITED STATES

124534 Waverly Hematology Oncology, 300 Asheville Ave, Suite 310, Cary, NC, 27518, UNITED STATES

124536 Wesley Medical Centre, PO Box 499, Toowong Qld 4066, AUSTRALIA

124537 Clinica oncologica; Col. Obispado, Cerro de la silla 815, 64060, Monterrey, MEXICO

124540 Hospital Universitario Austral, Unidad de Investigaciones Clinicas, 1500 AVENIDA JUAN DOMINGO PERON, B1629 Buenos Aires, ARGENTINA

124542 GEORGIA CANCER SPECIALISTS - MACON, 308 COLISEUM DRIVE, MACON (SUBURB OF TUCKER, 31217), TUCKER, GA, 30084, UNITED STATES

124544 Wake Forest University School of Medicine; Comprehensive Cancer Center, MEDICAL CENTER BLVD, WINSTON-SALEM, NC, 27157, UNITED STATES

124545 Aurora Bay Care Medical Center, 2845 Greenbrier Road, Green Bay, WI, 54311, UNITED STATES

124549 University of Missouri-Ellis Fischel; University Hospitals and Clinics, 1 HOSPITAL DRIVE, COLUMBIA, MO, 65212, UNITED STATES

124551 Aultman Hospital; Aultman Hospital Cancer Center, 2600 6th ST SW, Canton, 44710, UNITED STATES

124552 Drs. Forte, Schleider, Attas and Condemi, PA; Englewood Hospital and Medical Center, 350 Engle Street, Berrie Building 1st Floor, Englewood, NJ, 07631, UNITED STATES

124553 University of Hawaii, 1236 Lauhala Street, Honolulu, HI, 96813, UNITED STATES

124560 Nothwest Georgia Oncology Centers P.C, 340 Kennestone Hospital Blvd., Suite 200, Marietta, GA 30060, UNITED STATES

124561 Nothwest Georgia Oncology Centers P.C, 100 Market Place Blvd, Suite 200, Cartersville, GA, 30121, UNITED STATES

124563 Northwest Georgia Oncology Centers P.C., 157 Clinic Avenue, Suite 101, Carrolton, GA, 30117, UNITED STATES

124564 University of Southern California, USC Norris Comprehensive Cancer Center and Hospital, 1441 East Lake Avenue, Los Angeles, CA, 90033, UNITED STATES

124565 Breastlink Medical Group, Inc, 14650 Aviation Blvd., Hawthorne CA / USA,

124567 Providence Saint Joseph Medical Center; Research Department, 501 South Buena Vista Street, Burbank, CA, 91505-4866, UNITED STATES

124569 West Virginia University Hospitals Inc, 1 Medical Center Drive, P.O. Box 8110, Morgantown, WV, 26506-9162, UNITED STATES

124572 Medicine Hat Cancer Centre, 666 5th St SW, T1A 446, Medicine Hat, Alberta, CANADA

124575 Pacific Shores Medical Group, 17742 BEACH BLVD, HUNTINGTON BEACH, CA, 92647, UNITED STATES

124576 Central Hematology Oncology Medical Group Inc., 707 SOUTH GARFIELD AVENUE, SUITE 304, ALHAMBRA, CA, 91801, UNITED STATES

124577 ANTELOPE VALLEY CANCER CENTER; VIRGINIA K. CROSSON CANCER CENTER, 44105 15TH ST. WEST, SUITE 207, LANCASTER, CA, 93534, UNITED STATES

124580 Wilshire Oncology Medical Group, 50 Bellefontaine Street, Suite 304, Pasadena, CA, 91750, UNITED STATES

124583 North Valley Hematology/Oncology Medical Group; Providence Holy Cross Cancer Center, 15031 Rinaldi Street, Mission Hills, CA, 91345, UNITED STATES

124585 Santa Barbara Hematology / Oncology, 540 West Pueblo Street, Santa Barbara, CA, 93105, UNITED STATES

124587 Maryland Oncology Hematology, Medical Oncology, Oncology, Hematology, 2730 University Blvd W Ste 400, Silver Spring, MD 20902, , UNITED STATES

124589 York Hospital, 25 Monument Road, York, PA, 17403, UNITED STATES

124605 University of Kentucky Medical Center, 800 ROSE STREET, LEXINGTON, KY, 40536, UNITED STATES

124606 Kaiser Permanente, Roseville, 1001 Riverside, Roseville, CA, 95678, UNITED STATES

124608 VCU Massey Cancer Center at Stony Point, 9000 Stony Point Parkway, Second Floor, Richmond, Virginia 23235, UNITED STATES

124611 Florida Hospital, 2501 North Orange Ave Suite 800, SUITE 514, Orlando, FL, 32804, UNITED STATES

124616 ST. JUDE MEDICAL CENTER; VIRGINIA CROSSON CANCER CENTER, 100 EAST VALENCIA MESA DRIVE, SUITE 206, FULLERTON, CA, 92835, UNITED STATES

124617 William Beaumont Hospital, 3577 W 13 Mile Rd, Suite 404, Royal Oak, MI, 48073, UNITED STATES

124618 St. Vincent Frontier Cancer Center, 2900 12th Avenue North, Suite 160W, Billings, MT, 59101, UNITED STATES

124627 Decatur Memorial Hospital, 2300 N Edward St, Decatur, IL, 62526, UNITED STATES

124632 Rush University Medical Center - Chicago, 1653 W. Congress Parkway, 532 Jelke Building, Chicago, IL, 60612, UNITED STATES

124639 Monmouth Medical Center, 300 Second Avenue, Long Branch, NJ, 07740, UNITED STATES

124640 Covenant Health, JOE ARRINGTON CANCER RESEARCH & TREATMENT CENTER, 4101 22ND PLACE, LUBBOCK, TX, 79410, UNITED STATES

124641 UPMC CancerCenter at Magee-Womens Hospital of UPMC, 300 Halket Street, Pittsburgh, PA, 15213, UNITED STATES

124642 Oncology Alliance-Columbia, 2025 East Newport Avenue, Suite1000, Milwaukee, WI, 53211, UNITED STATES

124643 COMPREHENSIVE CANCER CENTERS OF NEVADA, Northwest Treatment Center, 7445 Peak Drive, LAS VEGAS, NV, 89128, UNITED STATES

124644 COMPREHENSIVE CANCER CENTERS OF NEVADA - HENDERSON, 10001 SOUTH EASTERN AVENUE, SUITE 108, HENDERSON, NV, 89052, UNITED STATES

124648 SUBURBAN HEMATOLOGY ONCOLOGY ASSOCIATES, 631 Professional Dr, Suite 450, Lawrenceville, GA, 30046, UNITED STATES

124650 SUBURBAN HEMATOLOGY-ONCOLOGY ASSOCIATES, 1700 TREE LANE, SUITE 490, SNELLVILLE, GA, 30078, UNITED STATES

124652 Kaiser Permanente - Hayward, 27400 Hesperian Blvd, 2nd Floor, Hayward, CA, 94545, UNITED STATES

124653 Providence Cancer Center Oncology and Hematology Care Clinic, Westside Portland, 9135 SW Barnes Road, Suite 261, Portland, OR, 97225, UNITED STATES

124654 Kaiser Permanente - Bellflower, 9400 E Rosecrans Ave, Bellflower, CA, 90706, UNITED STATES

124655 Kaiser Permanente - Riverside, 10800 Magnolia Avenue, Riverside, CA, 92505, UNITED STATES

124656 HOPITAL MAISONNEUVE- ROSEMONT; ONCOLOGY, PO#50096536, 5415 boul. de l'Assomption, H1T 2M4, Montreal, Quebec, CANADA

124657 The First Affiliated Hospital of College of Medicine, Zhejiang University(First Hospital of Zhejiang, No.79 Qingchun Road, 310003, Hangzhou, CHINA

124660 ST. LUKE'S ROOSEVELT HOSPITAL CENTER, 1000 10TH AVENUE, SUITE 11C, NEW YORK, NY, 10019, UNITED STATES

124668 Evangelisches Krankenhaus Bethesda GmbH, Medizinische Klinik, Ludwig-Weber-Str. 15, 41061, Mönchengladbach, GERMANY

124669 INSTITUT OF ONCOLOGY AL. TRESTIOREANU BUCHAREST; ONCOLOGY, Sos. Fundeni nr. 252, 022328, Bucuresti, ROMANIA

124672 NORTHWEST GEORGIA ONCOLOGY CENTERS, 531 Roselan Street NW, Marietta, 30060, UNITED STATES

124675 Akron City Hospital, 525 E Market Street, Akron, OH, 44304, UNITED STATES

124683 University of Iowa, 9500 Euclid Avenue, R35, Cleveland, OH, 52242-1086, UNITED STATES

124685 Stanford University Medical Center, 300 Pasteur Dr, Stanford, CA, 94305, UNITED STATES

124687 Peninsula Regional Medical Center, 100 E Carroll St, Salisbury, MD, 21801, UNITED STATES

124692 Toledo Clinic Cancer Centers, 4126 N. Holland Sylvania, Road, Suite 105, Toledo, OH 43623, UNITED STATES

124694 Renown Regional Medical Center, 236 W 6th Street, Reno, NV, 89503, UNITED STATES

124697 HARTFORD HOSPITAL, 80 Seymour St., JB 704, Hartford, CT, 06102, UNITED STATES

124698 Kaiser Permanente Sacramento Medical Center, 2025 Morse Ave, Sacramento, CA, 95825, UNITED STATES

124699 Providence Medical Group, 2723 S. 7th Street, Terre Haute, IN, 47802, UNITED STATES

124700 Marquette General Hospital, 580 West College Avenue, Marquette, MI, 49855, UNITED STATES

124701 Aurora Cancer Care-Milwaukee West, 1055 N. Mayfair Road, Suite 200, 53226-3436 Wauwatosa, USA

124708 Medical Oncology Associates, 3075 Health Center Drive, Suite 102, San Diego, CA, 92123, UNITED STATES

124713 Facharzte fur Innere Medizin und Hamatologie und Onkologie, Wasserburger Str. 29, 83278, Traunstein, GERMANY

124715 UCLA Healthcare/Pasadena Oncology, 55 East California, Pasadena, CA, 91105, UNITED STATES

124716 LKH-UNIV. KLINIKUM GRAZ; KLINIK FÜR INNERE MEDIZIN I, AUENBRUGGERPLATZ 15, 8036, GRAZ, AUSTRIA

124717 KRANKENHAUS DER BARMHERZIGEN BRUEDER; INTERNE ABT., MARSCHALLGASSE 12, 8020, GRAZ, AUSTRIA

124718 ISTITUTO REGINA ELENA; ONCOLOGIA MEDICA A, Via Elio Chianesi, 53, 00168, Roma, Lazio, ITALY

124719 Allegheny General Hospital, 420 East North Avenue, Pittsburgh, PA, 15212, UNITED STATES

124720 Berdat Family Cancer Centre, C203 12 Salvado Rd Subiaco, 5507 Subiaco, 6008, Perth, Western Australia, AUSTRALIA

124721 University of Tennessee Cancer Institute, 7945 Wolf River Blvd., Suite 300, Germantown, TN, 38138, UNITED STATES

124724 University of Tennessee Cancer Institute, The West Clinic, 7668 Airways Blvd., South Haven, MS, 38671, UNITED STATES

124725 Interlakes Oncology & Hematology, P.C., 211 WHITE SPRUCE BLVD, Suite 120, ROCHESTER, NY, 14623, UNITED STATES

124726 Interlakes Oncology & Hematology, P.C., 675 W. Washington Street, Geneva, NY, 14456, UNITED STATES

124730 Interlakes Oncology & Hematology, P.C., 360 Parrish Street, Canandaigua, NY, 14424, UNITED STATES

124736 North Estonia Medical Centre Foundation; Oncology Centre, Hiiu 44, Tallinn, 11619, Tallin, ESTONIA

124744 Mountain States Tumor Inst, 656 Addison Avenue West, Twin Falls, ID, 83301, UNITED STATES

124747 Mountain States Tumor Inst, 520 South Eagle Road, Meridian, ID, 83642, UNITED STATES

124750 Hopital Dupuytren; Oncologie Medicale, 2 Avenue Martin Luther King, CEDEX 1, 87042, Limoges, FRANCE

124751 KLINIK FULDA; MEDIZINISCHES VERSORGUNGSZENTRUM, Pacelliallee 4, 36043, Fulda, GERMANY

124752 IST. UNI FEDERICO II; DIVISIONE DI ONCOLOGIA MEDICA - DPT. DI MEDICINA INTERNA, VIA PANSINI 5, 80131, NAPOLI, Campania, ITALY

124756 Munson Medical Center, 1105 Sixth Street, Traverse City, MI, 49684, UNITED STATES

124760 Cancer Research Consortium of West Michigan, 25 Michigan St., NE, Grand Rapids, MI, 49503, UNITED STATES

124764 SUTTER INST. FOR MEDICAL RESEARCH, 1020 29TH STREET, SUITE 580, SACRAMENTO, CA, 95816, UNITED STATES

124765 Centre Leonard De Vinci;Chimiotherapie, Route de Cambrai, 59187, Dechy, FRANCE

124766 Fondazione Salvatore Maugeri, Via Maugeri 8, 27100, Pavia, Lombardia, ITALY

124767 Hospital San Pedro de Alcantara, Avda Pablo Naranjos s/n, 10310, Caceres, CACERES, SPAIN

124775 Instituto do Cancer do Estado de Sao Paulo - ICESP, Avenida Dr. Arnaldo, 251 - Quinto andar, Cerqueira Cesar, 01246-000, Sao Paulo, SP, BRAZIL

124777 Althaia Xarxa Assistencial de Manresa, Calle Dr. Joan Soler 1-3, 08243, Manresa, BARCELONA, SPAIN

124778 Cancer Center of NC at Asheville, 20 Medical Park Dr, Asheville, NC, 28803, UNITED STATES

124779 National Cancer Institute - NEW KASR AL AINI HOSPITAL; HEMATOLOGY, Kasr Al Eini STREET, Fom El Khalig, 11796, CAIRO, EGYPT

124780 Klinikum Sindelfingen-Böblingen; Frauenklinik, Bunsenstraße 120, 71032, Böblingen, GERMANY

124785 Cancer Specialists of North Florida - Jacksonville (Booth Rd), 5742 Booth Road, Jacksonville, FL, 32207, UNITED STATES

124787 Cancer Specialists of North Florida - Jacksonville Beach, 1375 Roberts Drive, Suite 103, Jacksonville Beach, FL, 32250, UNITED STATES

124788 Integrated Community Oncology Network - Orange Park, 2161 Kingsley Ave, Suite 200, Orange Park, FL, 32073, UNITED STATES

124789 Integrated Community Oncology Network - Jacksonville (Prudential Dr), 841 Prudential Drive, Jacksonville, FL, 32207, UNITED STATES

124790 Cancer Specialists of North Florida - Jacksonville (St Augustine Rd), 14546 St. Augustine Road, Jacksonville, FL, 32258, UNITED STATES

124791 Cancer Specialists of North Florida - Jacksonville (Shircliff Way), 2 Shircliff Way, Jacksonville, FL, 32204, UNITED STATES

124795 Med Star Franklin Square Medical Center/Weinburg Cancer Institute, 9103 Franklin Square Dr, Suite 2300, Baltimore, MD, 21237, UNITED STATES

124796 Kaiser Permanente Rock Creek, 280 Exempla Circle, Lafayette, CO, 80026, UNITED STATES

124798 Breastlink at the Breast Care Imaging Center of Orange County, 230 S. Main Street, Suite 100, Orange, CA, 92868, UNITED STATES

124813 Hesky, Fisher, Luknic and Cook, 2005 Franklin, Denver, CO, 80205, UNITED STATES

124817 MORRISTOWN MEDICAL CENTER;HEMATOLOGY-ONCOLOGY ASSOC, Carol G. Simon Cancer Center, 100 Madison Avenue Morristown, NJ 07960, UNITED STATES

124818 Emory Univ Winship Cancer Inst, 1365A Clifton Rd, NE, Suite 3012, Atlanta, GA, 30322, UNITED STATES

124819 Berkshire Medical Center, BERKSHIRE HEMATOLOGY, ONCOLOGY PC, 165 TOR Court, PITTSFEILD, MA, 01201, UNITED STATES

124822 Upper Peninsula Hematology/Oncology Associates, 1414 W. Fair Avenue, Suite 332, Marquette, MI, 49855, UNITED STATES

124823 Reno Oncology Associates, 85 Kirman Avenue, Suite#101, Las Vegas, NV, 89502, UNITED STATES

124827 St. John's Regional Health Center-Joplin, 2727 McClelland Blvd., Suite 1, Joplin, MO, 64804, UNITED STATES

124828 Norton Cancer Institute, 4950 Norton Healthcare Blvd Ste 300, Louisville, KY 40241, , UNITED STATES

124832 Ben Taub General Hospital - HCHD, 1504 Taub Loop, Houston, TX, 77030, UNITED STATES

124833 HENRY FORD HOSPITAL; JOSEPHINE FORD CANCER CENTER, 2799 WEST GRAND BLVD, CLINICAL TRIALS OFFICE, DETROIT, MI, 48202-2689, UNITED STATES

124834 Christiana Care Health System, Medical Oncology Hematology Consultants, 4701 Ogletown-Stanton Road, S-3400, Newark, DE, 19713, UNITED STATES

124835 GREATER BALTIMORE MEDICAL CENTER, 6569 N. Charles Street, Baltimore, MD, 21204, UNITED STATES

124837 Freeman Cancer Institute, 3415 McIntosh Circle Drive, Joplin, MO, 64804, UNITED STATES

124838 Hematology/Medical Oncology Consultants, 1351 W. Central Park, Davenport, IA, 52804, UNITED STATES

124841 Cancer and Blood Specialists of Nevada, 701 Shadow Lane, Suite 300, Las Vegas, NV, 89106, UNITED STATES

124847 Nevada Cancer Research Foundation, Cancer Consultants, 501 S Rancho Dr, Ste H53, Las Vegas, NV, 89106, UNITED STATES

124862 Carolinas Health Care System, Levine Cancer Institute, Research + Academic Headquartes, 1025 Morehead Medical Drive, Charlotte, NC, 28204-2839, UNITED STATES

124863 Overlook Hospital, 99 Beauvois Avenue, Summit, NJ, 07902, UNITED STATES

162645 McKay-Dee Cardiology Clinic, 4401 Harrison Blvd., Suite 3960, Ogden, UT, 84403, UNITED STATES

162651 Cancer Consultants, 2020 W. Palomino Lane, Las Vegas, NV, 89106, UNITED STATES

162654 Michiana Hematology- Oncology, P.C., South Bend Indiana, 615 N Michigan St, Suite 5550, South Bend, IN, 46601, UNITED STATES

162669 Stony Brook University Hospital, 3 Edmund D. Pellegrino Road, Stony Brook, NY, 11794, UNITED STATES

162700 Waterford Regional Hospital; Department Of Medical Oncology, DUNMORE RD, WATERFORD, IRELAND

162767 Adelaide & Meath Hospital, Dublin, Incorporating the National Children's Hospital, TALLAGHT, DUBLIN, 24, IRELAND

162968 St. Elisabeth Krankenhaus Köln GmbH; Gynäkologie und Geburtshilfe, Werthmannstrasse 1, 50935, Koeln, GERMANY

162978 CLINIQUE TIVOLI; SCE RADIOTHERAPIE, 91 Rue De Riviere BP 114, 33000, Bordeaux, FRANCE

163035 Credit Valley Hospital/Carlo Fidani Peel Regional Cancer Centre, 2200 EGLINTON AVENUE WEST, L5M 2N1, MISSISSAUGA, Ontario, CANADA

163036 Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe, Starkenburgring 66, 63069, Offenbach, GERMANY

163037 Klinikum Frankfurt Höchst GmbH; Klinik für Gynäkologie und Geburtshilfe, Gotenstr. 6-8, 65929, Frankfurt, GERMANY

163634 Texas Oncology-Baylor Charles A. Sammons Cancer Center, 3410 Worth Street, DALLAS, 75246, UNITED STATES

163843 UMDMJ-New Jersey Medical School, 185 SOUTH ORANGE AVENUE, MSB I-594, UNIVERSITY HEIGHTS, NEWARK, NJ, 07103-2714, UNITED STATES

163844 Oncology Care Medical Associates, 12535 E. Washington Blvd., Whittier, CA, 90602, UNITED STATES

163845 SZENT MARGIT HOSPITAL; DEPT. OF ONCOLOGY, BECSI UT 132, 1032, BUDAPEST, HUNGARY

163847 MATER MISERICORDIAE UNI HOSPITAL; ONCOLOGY, ECCLES STREET, DUBLIN, 7, IRELAND

163849 Hospital Universitario la Fe; Servicio de Oncologia, C\ Bulevar Sur s/n, 46026, Valencia, VALENCIA, SPAIN

163851 Arizona Oncology Associates, PC - NAHOA, 3700 W State Route 89A, Sedona, AZ, 86336, UNITED STATES

163853 Texas Oncology - Dallas Presbyterian Hospital, 8220 WALNUT HILL LANE, DALLAS, 75231, UNITED STATES

163854 Virginia Cancer Specialists, PC, 8503 Arlington Boulevard, SUITE 400, PROSPERITY CENTER MEDICAL OFFICE, Fairfax, VA, 22031, UNITED STATES

163855 Texas Oncology-Medical City Dallas, 7777 FOREST LANE, SUITE D-400, DALLAS, TX, 75230, UNITED STATES

163948 Hospital Perpetuo Socorro, Servicio de Oncología, Avenida de Damián Tellez Lafuente, s/n, 06010, Badajoz, BADAJOZ, SPAIN

163974 Instituto Nacional do Cancer - INCA, Rua Visconde de Santa Isabel, Bairro Vila Isabel, 20560-120, Rio de Janeiro, RJ, BRAZIL

163976 OVERLAKE INTERNAL MEDICINE ASSOCIATES, 1135 116th Avenue NE, Suite 23, Bellevue, WA, 98004, UNITED STATES

164047 LONDON REGIONAL CANCER CENTRE, 790 COMMISSIONERS ROAD EAST, N6A 4L6, LONDON, Ontario, CANADA

164049 Central Utah Clinic PC, 1055 North 300 West, Bldg. B, Provo, UT, 84004, UNITED STATES

164294 Rockwood Cancer Treatment Center, 12410 E. Sinto Avenue, Suite 101, Spokane, WA, 99204, UNITED STATES

164341 Intermountain Medical Center Jon and Karen Huntsman Cancer Center, 5169 S Cottonwood Street, Murray, UT, 84157, UNITED STATES

164403 Texas Oncology - Houston (Gessner), 925 Gessner, Suite 550, Houston, TX, 77024, UNITED STATES

164404 EL PASO CANCER TREATMENT CENTER, 7848 GATEWAY EAST, EL PASO, TX, 79915, UNITED STATES

164405 EL PASO CANCER TREAT CTR WEST, 1901 GRANDVIEW, EL PASO, 79902, UNITED STATES

164407 Cancer Care & Hematology Specialists of Chicagoland, 880 W. Central Road, Arlington Heights, 60005, UNITED STATES

164408 VIRGINIA ONCOLOGY ASSOCIATES - LAKE WRIGHT CANCER CENTER, 5900 LAKE WRIGHT DRIVE, NORFOLK, VA, 23502, UNITED STATES

164424 ROCKY MOUNTAIN CANCER CENTER; MEDICAL ONCOLOGY, 1800 WILLIAMS STREET, SUITE 200, DENVER, CO, 80218, UNITED STATES

164630 Hospital Universitario Puerta del Mar; Servicio de Oncologia, Avda. Ana De Viya 21, 11009, Cádiz, CADIZ, SPAIN

164631 Fundacion Jimenez Diaz; Servicio de Oncologia, AVDA DE LOS REYES CATÓLICOS 2, 28040, MADRID, MADRID, SPAIN

164672 Riddle Hospital, 1068 WEST BALTIMORE PIKE, MEDIA, PA, 19063, UNITED STATES

164675 Virginia Oncology Associates - New Port News, 1051 Loftis Boulevard, New Port news, VA, 23606, UNITED STATES

164676 North Texas Regional Cancer Center, 3705 W 15TH STREET, PLANO, 75075-7787, UNITED STATES

164678 Hematology-Oncology Associates of NE PA, 1100 MEADE STREET, DUNMORE, PA, 18512, UNITED STATES

164679 Cancer Care Centers of South Texas, 2130 NE Loop 410, San Antonio, TX, 78217, UNITED STATES

164724 San Antonio Tumor & Blood Clinic, 540 Madison Oak Drive, San Antonio, 78258, UNITED STATES

164774 Leopoldina Krankenhaus der Stadt Schweinfurt GmbH, Gustav-Adolf-Str. 8, 97422, Schweinfurt, GERMANY

164792 NORTHWEST CANCER SPECIALISTS, 210 SE 136th Ave., Vancouver, WA 98684, UNITED STATES

164905 Christie Hospital; Breast Cancer Research Office, 1st Floor, Manchester, M20 4BX, UNITED KINGDOM

164906 EPHRATA CANCER CENTER, 460 North Reading Road, Ephrata, PA, 17522, UNITED STATES

165137 JILIN CANCER HOSPITAL, 1018 Huguang Road, Chaoyang District, 130012, Changchun, CHINA

165138 Sun Yet-sen University Cancer Center, 651 DONG FENG ROAD EAST, 510060, GUANGZHOU, CHINA

165139 Fuzhou General Hospital, PLA Nanjing Military Area Command, No.156 Bei Lu, Xi'er Huan, Fujian, 354200, Fuzhou, CHINA

165141 Tianjin Cancer Hospital, Huanhuxi Road, North Tiyuan, Hexi District, 300060, Tianjin, CHINA

165142 General Hospital of Chinese PLA; Department of Hematology, No.28, Fuxing Road, Haidian District, 100853, Beijing, CHINA

165143 West China Hospital, Sichuan University, 37 Guo Xue Xiang, 610041, Chengdu, CHINA

165215 Mid Ohio Oncology Hematology; ZangMeister Center (West), 3100 Plaza Properties Blvd., Columbus, OH, 43219, UNITED STATES

165220 VELINDRE CANCER CENTRE; ONCOLOGY DEPT, VELINDRE ROAD, WHITCHURCH, CARDIFF, CF14 2TL, UNITED KINGDOM

165261 TARTU UNI HOSPITAL; HEMATOLOGY - ONCOLOGY CLINIC, PUUSEPA 8, 51014, TARTU, ESTONIA

165295 Sparta Cancer Treatment Center, 89 Sparta Avenue, Sparta, NJ, 07871, UNITED STATES

167015 Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Dr Esquerdo, 46, 28007, Madrid, MADRID, SPAIN

167364 Fudan University Shanghai Cancer Center, 270, Dongan Road, 200032, Shanghai, CHINA

167365 Hematology Oncology Care Inc., 5310 Rapid Run, Suite 202, Cincinnati, OH, 45238, UNITED STATES

124285 Queen Mary Hospital, 102 Pokfulam Road
Hong Kong SAR, China

124574 KAISER PREMANENTE Franklin Medical Offices, 2045 Frankln Street, Denver, CO, 80205, UNITED STATES

124609 PROVIDENCE PORTLAND, Medical Center, 4805 NE Glisan St. Portland, OR 97213, USA

124666 Oncology Hematology Care, Inc., 5053 Wooster Road, Cincinnati, OH 45226, USA